Nitrilotriacetic acid linker, solid-phase synthesis of nitrilotriacetic acid linker and application of nitrilotriacetic acid linker

By modifying the metal layer with subaminotriacetic acid linker, the problems of low protein fixation and dissociation efficiency and difficult to correct flow channel drift are solved, and the stability and accuracy of biosensing are improved.

CN119072631APending Publication Date: 2024-12-03NICOYA LIFESCI INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380022667.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-12
Filing Date
2023-10-11
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing NTA sensor chips have slow and unstable problems when fixing and dissociating proteins, and the drift of the circulation tank is difficult to correct, limiting their wide application in biosensing.

Method used

A sub-aminotriacetic acid linker is used to form a tunable linker by combining NTA functional groups with amino acid groups and carbon chains, which is used to modify the metal layer, improve the fixation and dissociation efficiency of proteins, and through improved process methods Implement its application in SPR or LSPR sensors.

Benefits of technology

It realizes efficient fixation and dissociation of proteins, reduces the drift problem of circulation tanks, improves the stability and repeatability of the sensor, and enhances the accuracy and reliability of biosensing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072631A_ABST
    Figure CN119072631A_ABST
Patent Text Reader

Abstract

Devices, compounds, and methods for detecting an analyte in a sample are described. More specifically, the present disclosure provides surface plasmon resonance or localized surface plasmon resonance sensors that are modified with a nitrilotriacetic acid linker to bind to a ligand and / or an analyte. The nitrilotriacetic acid linkers of the present disclosure generally include a head (or an "anchor site") for coupling to a surface of a surface plasmon resonance or localized surface plasmon resonance sensor, a spacer, and one or more attachment sites located distal or terminus of the spacer, the attachment sites coupled to a ligand. The head may include a thiol for coupling a linker to a surface of a surface plasmon resonance or localized surface plasmon resonance sensor. The spacer may be a carbon chain, a PAG or PEG chain, or a matrix material. The one or more attachment sites may be a nitrilotriacetic acid (NTA) moiety capable of sequestering a transition metal ion and a binding ligand, and the one or more attachment sites may be a nitrilotriacetic acid (NTA) moiety capable of sequestering a transition metal ion and a binding ligand.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 379,207, filed on October 12, 2022, which is incorporated herein by reference in its entirety.

[0003] Incorporated by Reference

[0004] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0005] field

[0006] The subject matter generally relates to linkers or solid phase synthesis of nitrilotriacetic acid linkers and their use in biosensing applications utilizing surface plasmon resonance. Background Art

[0007] Surface plasmon resonance (SPR) and localized surface plasmon resonance (LSPR) spectroscopy are used in a variety of analytical methods, such as quantitative, kinetic, and thermodynamic studies. SPR and LSPR provide a label-free method to detect molecular binding events of analytes such as DNA, proteins, and polymers in real time. Current applications of SPR and LSPR use self-assembled monolayers (SAMs) composed of thiol-containing groups attached to a gold surface, either a thin gold film or a gold nanoparticle, with alkyl groups extending from the gold surface and a carboxylic acid group at the end of the chain.

[0008] SPR and LSPR are used to detect protein-protein or protein-ligand interactions by immobilizing a protein analyte on the chip surface using high affinity interactions such as antibody capture, streptavidin / biotin, or covalent coupling using amino groups to directly visualize the binding of a ligand to the immobilized component. Once a protocol for immobilizing a specific analyte on the sensor surface is established, binding affinity can be determined in an automated manner, and interacting partners can be screened. However, in our experience, determining the best method to immobilize a protein analyte and obtain a stable surface with high binding capacity can be tedious.

[0009] Since the first report of immobilized metal ion affinity chromatography (IMAC), several modified methods have been developed. Among them, Ni immobilized by chelation with nitrilotriacetic acid (NTA) bound to a solid support 2+ It has become the most commonly used method for purifying proteins with histidine (His) tags.

[0010] Different types of NTA-based sensors have been reported, including NTA-modified glass-based surfaces, NTA-functionalized dextran hydrogels, and NTA-terminated (alkyl)thiol SAMs, as well as solid-supported lipid bilayers doped with NTA lipids. The availability of commercially available nitrilotriacetic acid (NTA) sensor chips allows for repeated immobilization, stripping, and regeneration of His6-tagged proteins; however, this immobilization method has several drawbacks that prevent its widespread use. First, although the NTA / His6 interaction is strong, slow and continuous dissociation of the immobilized component is common. Computational methods can be used to correct for decay surfaces post hoc; however, this solution is not ideal. The second common problem with NTA sensor chips is the idiosyncratic drift of the flow cell. If all flow cells drift equivalently, dual referencing can be used to correct for systematic biases in all flow cells; however, we often encounter biases that occur only in a single flow cell and cannot be corrected using this method. Summary of the invention

[0011] In some aspects, the present disclosure relates to a nitrilotriacetic acid linker having the following chemical formula:

[0012]

[0013] In some embodiments, the AA group comprises a linear or branched natural or synthetic amino acid group, which includes one or more amino acids. In some embodiments, the optional spacer includes a linear or branched carbon chain, which includes one or more amino acids, a polymer portion, or any combination thereof. In some embodiments, in the absence of the spacer, the AA group is coupled to the one or more nitrilotriacetic acid (NTA) groups. In some embodiments, the nitrilotriacetic acid (NTA) group includes one or more nitrilotriacetic acid functional groups. In some embodiments, wherein R is H, a short chain alkyl, or an NTA group. In some embodiments, "n" is the number of spacers in the linker. In some embodiments, "n" includes 0 to 50 spacers. In some embodiments, "o" is the number of NTA groups in the linker. In some embodiments, "o" includes 1 to 10 NTA groups. In some embodiments, Where "p" is the number of parts.

[0014] In some embodiments, "p" comprises 1 to 10 moieties.

[0015] In some aspects, the AA group includes 1 to 10 amino acids. In some embodiments, the AA group includes a cysteine ​​or a methionine amino acid.

[0016] In some aspects, the nitrilotriacetic acid linker comprises a spacer. In some embodiments, the spacer comprises a carbon chain. In some embodiments, the spacer comprises a PAG group having one or more PAG units. In some embodiments, the spacer comprises a PEG group having one or more PEG units.

[0017] In some embodiments, the one or more NTA groups are configured to be coupled to a ligand and / or an analyte.

[0018] In some aspects, the present disclosure relates to a surface plasmon resonance (SPR) or localized surface plasmon resonance (LSPR) sensor comprising: (a) a substrate, wherein the substrate comprises a solid support coated with a metal layer; and (b) a primary aminotriacetic acid (NTA) linker. In some embodiments, the AA group of the NTA linker is coupled to the metal layer. In some embodiments, one or more NTA functional groups of the linker are capable of binding to one or more ligands and / or analytes.

[0019] In some embodiments, the sensor comprises a substrate and a coating. In some embodiments, the AA group is covalently coupled to the coating. In some embodiments, the substrate is selected from the group consisting of a silicon substrate, a glass substrate, a polystyrene substrate, and an agarose substrate. In some embodiments, the coating comprises a first inner coating and a second outer coating. In some embodiments, the first inner coating comprises a polyelectrolyte or a poly(allylamine hydrochloride). In some embodiments, the second outer coating comprises a metal coating, a gold film, a metal nanoparticle coating, or a gold nanoparticle coating.

[0020] In some aspects, the present disclosure relates to a method of using a surface plasmon resonance (SPR or LSPR) sensor to detect an analyte in a fluid, the method comprising the steps of: providing an SPR or LSPR sensor comprising a surface, the surface comprising a solid support, the solid support coated with a metal layer and having a NITA linker attached to the metal layer; contacting a fluid containing an analyte with the SPR or LSPR sensor; and measuring an optical signal to detect a change in the optical signal in response to the contacting, thereby measuring the analyte in the fluid. In some embodiments, the NITA linker is configured to bind one or more ligands.

[0021] In some aspects, the present disclosure relates to a method for preparing a sensor coupled to the nitrilotriacetic acid linker, the method comprising the steps of: providing a substrate; coupling a first AA group to the substrate to produce substrate-AA; optionally, coupling a spacer to the first AA group to produce substrate-AA-spacer, and the spacer includes an amino acid at the first end of the spacer; and reacting the terminal amino acid with a first reagent to produce a nitrilotriacetic acid linker.

[0022] In some embodiments, the substrate is selected from the group consisting of a silicon substrate, a glass substrate, a polystyrene substrate, and an agarose substrate.

[0023] In some embodiments, the AA group includes a substrate coupling group and an α-amino group.

[0024] In some embodiments, the spacer comprises a first coupling group at a first site, a second coupling group at a second site, and optionally a third coupling group at a third site. In some embodiments, the first coupling group, the second coupling group, and the optional third coupling group may be the same or different chemical functional groups.

[0025] In some embodiments, the first AA group further comprises one or more protecting groups. In some embodiments, the one or more protecting groups on the first AA group comprise one or more trityl functional groups and / or one or more fmoc functional groups. In some embodiments, the AA group comprises an fmoc-protected α-amino group, a trityl-protected thiol functional group, and a carboxyl group, the carboxyl group reacting with a substituent on the substrate to covalently bind to the substrate. In some embodiments, a second reagent is used to remove the fmoc-protected α-amino group in the AA group to obtain a deprotected α-amino group.

[0026] In some embodiments, the spacer further comprises one or more protecting groups. In some embodiments, the one or more protecting groups on the spacer comprise one or more fmoc functional groups and one or more tert-butyl functional groups. In some embodiments, the spacer comprises an fmoc-protected amino group and a carboxyl group, the carboxyl group reacts with the deprotected α-amino group on the AA group to covalently bind to the AA group. In some embodiments, a second reagent is used to remove the fmoc-protected amino group of the spacer to obtain a functional group, and wherein the functional group reacts with a second AA to obtain a deprotected amino group.

[0027] In some embodiments, the second AA includes one or more protecting groups. In some embodiments, the one or more protecting groups on the second AA include one or more fmoc functional groups and / or one or more tert-butyl functional groups. In some embodiments, the second AA includes an fmoc-protected α-amino group, the tert-butyl functional group and a carboxyl group, which reacts with the deprotected amino group on the spacer to covalently bind to the spacer. In some embodiments, the fmoc-protected α-amino group on the second AA is removed to produce a deprotected α-amino group. In some embodiments, the deprotected α-amino group is reacted with a second reagent to produce an NTA-tBu functional group. In some embodiments, the first reagent is used to remove the tert-butyl protecting group on the second AA to produce the nitrilotriacetic acid linker.

[0028] In some embodiments, the spacer comprises a hydrophilic modification. In some embodiments, the hydrophilic modification comprises a PAG group having one or more PAG units. In some embodiments, the hydrophilic modification comprises a PEG group having one or more PEG units.

[0029] In some embodiments, the NITA linker is separated from the substrate.

[0030] In some embodiments, the first AA group comprises fmoc-D-Cys(Trt)-OH or Fmoc-D-Met-OH.

[0031] In some embodiments, the first AA group comprises a series of amino acids, wherein one amino acid comprises a moiety for attachment to the substrate, and another amino acid comprises a moiety having an alpha amino group adjacent to a carboxyl group.

[0032] In some embodiments, the spacer comprises fmoc-11-aminoundecanoic acid.

[0033] In some embodiments, the second AA comprises Fmoc-Glu-OtBu.

[0034] In some embodiments, the first reagent includes iodoacetic acid (IAA) and diisopropylethylamine (DIPEA).

[0035] In some embodiments, the second reagent comprises 20% piperidine in a solution of dimethylformamide (DMF), trifluoroacetic acidm TFA and triisopropylsilane (TIS) or trifluoroacetic acid (TFA), dimethyl sulfoxide (DMSO) and anisole.

[0036] In some aspects, the present disclosure relates to a sensor for reversibly capturing multiple analytes in a sample, the sensor comprising: a metal nanoparticle configured to generate a light signal; a substrate disposed on a portion of a surface of the metal nanoparticle; and a plurality of multidentate groups bound to the substrate, wherein each of the plurality of multidentate groups chelates with a metal ion.

[0037] In some embodiments, the matrix comprises a polysaccharide, a polysaccharide derivative, a polymer, a functionalized polymer, a protein, or a combination thereof.

[0038] In some embodiments, the matrix comprises dextran or carboxymethylated dextran.

[0039] In some embodiments, the metal ion comprises a transition metal ion.

[0040] In some embodiments, the transition metal ion is selected from the group consisting of nickel, iron, cobalt, copper, zinc, or a combination thereof.

[0041] In some embodiments, the plurality of polydentate groups comprises nitrilotriacetic acid, tris-(2-aminoethyl)amine, or a combination thereof.

[0042] In some embodiments, the matrix comprises dextran, and the plurality of tridentate groups are nitrilotriacetic acid.

[0043] In some embodiments, the matrix comprises a matrix thickness of about 1 nm to about 100 nm.

[0044] In some embodiments, the sensor comprises a density of multidentate groups of about 1% to about 100%. In some embodiments, the sensor comprises a density of multidentate groups of about 25% to about 75%.

[0045] In some embodiments, the matrix is ​​covalently bound to the metal nanoparticles.

[0046] In some aspects, the present disclosure relates to a method of forming a sensor medium, the method comprising: thiolation of a matrix material to provide a thiolated matrix material; adding at least one multidentate group to the thiolated matrix material to provide a modified matrix material; and disposing the modified matrix material on a portion of a surface of a metal substrate.

[0047] In some embodiments, a host material is thiolated to provide a thiolated host material, and then at least one multidentate group is added to the thiolated host material to provide a modified host material.

[0048] In some embodiments, the step of thiolation of a host material comprises combining the host material with an amine or a derivative thereof. In some embodiments, the amine comprises a mercaptoalkylamine.

[0049] In some embodiments, each of the at least one multidentate group comprises -SR, -OR, -NR2, -COOR, -CO, heterocycloalkyl, or a combination thereof. In some embodiments, R is independently H, a substituted or unsubstituted C1-C4 alkyl, or a combination thereof. In some embodiments, the at least one multidentate group is nitrilotriacetic acid, tris-(2-aminoethyl)amine, tris(hydroxymethyl)aminomethane, or a combination thereof.

[0050] In some embodiments, the metal substrate includes metal nanoparticles.

[0051] In some embodiments, the method further comprises chelating at least one polydentate group with a metal ion. In some embodiments, the metal ion comprises a transition metal ion selected from nickel, iron, cobalt, copper, calcium, zinc, or a combination thereof.

[0052] In some aspects, the present disclosure relates to a method for determining the presence of an analyte in a sample, the method comprising the steps of: providing a sensor modified with CMD-NTA; contacting the sensor with the sample, the sample comprising the analyte; and binding the analyte to the sensor to generate a signal corresponding to the analyte. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] The novel features of the present disclosure are set forth in detail in the appended claims. The features and advantages of the present disclosure will be better understood by reference to the following detailed description, which sets forth illustrative embodiments utilizing the principles of the present disclosure, and is accompanied by the accompanying drawings, in which:

[0054] Figure 1 An exemplary SPR sensor system according to the principles described herein is illustrated.

[0055] Figure 2 An exemplary LSPR metal nanoparticle sensor system according to the principles described herein is illustrated.

[0056] FIG. 3A to FIG. 3C Exemplary SPR or LSPR tunable linker molecules are illustrated with varying densities of attachment sites and spacer molecules.

[0057] Figure 4 Exemplary SPR or LSPR tunable linker molecules with different amino acids are illustrated.

[0058] Figure 5 Illustrated are sensorgrams of nanoparticles coated with NTA-modified carboxymethyldextrose (CMD-NTA) after exposure to anti-IL-6 antibodies in the presence and absence of IL-6.

[0059] Figure 6 is a graph showing the IL-6 ligand immobilization response of four independent channels (ie, 4 different CMD-NTA modified sensors).

[0060] Figure 7 is a graph showing the IL-6 analyte immobilization response of four independent channels (ie, 4 different CMD-NTA modified sensors). DETAILED DESCRIPTION

[0061] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols generally represent similar parts unless the context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not intended to be limiting. Other embodiments may be used, and other changes may be made, without departing from the scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure as generally described herein and shown in the drawings may be arranged, substituted, combined, separated, and designed in a variety of different configurations, all of which are expressly contemplated herein.

[0062] Although certain embodiments and examples are disclosed below, the subject matter of the invention extends beyond the specifically disclosed embodiments to other alternative embodiments and / or uses, as well as modifications and equivalents thereof. Therefore, the scope of the claims appended hereto is not limited by any specific embodiment described below. For example, in any method or process disclosed herein, the actions or operations of the method or process may be performed in any suitable order, and are not necessarily limited to any particular disclosed order. Various operations may be described in sequence as multiple discrete operations, which helps to understand certain embodiments, however, the order of description should not be interpreted as implying that such operations are sequence-dependent. In addition, the structures, systems and / or devices described herein may be embodied as integrated components or separate components.

[0063] For the purpose of comparing various embodiments, certain aspects and advantages of such embodiments are described. Not all such aspects or advantages are necessarily achieved by any particular embodiment. Thus, for example, various embodiments may be performed in a manner that achieves or optimizes an advantage or group of advantages taught herein without necessarily achieving other aspects or advantages taught or suggested herein.

[0064] Terms, Definitions and Abbreviations:

[0065] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs.

[0066] As used herein, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Any reference to "or" herein is intended to include "and / or" unless otherwise stated.

[0067] As used herein, the term "about" in certain cases refers to an amount that is approximately the stated amount.

[0068] As used herein, the term "about" refers to an amount that approximates 10%, 5%, or 1% of the stated amount, including increments therein.

[0069] As used herein, the term "about" when referring to a percentage, refers to an amount that is greater or less than 10%, 5%, or 1%, including increments therein.

[0070] As used herein, the phrases "at least one," "one or more," and "and / or" are open-ended expressions that are both conjunctions and disjunctions in operation. For example, each of the expressions "at least one of A, B, and C," "at least one of A, B, or C," "one or more of A, B, and C," "one or more of A, B, or C," and "A, B and / or C" all mean A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B, and C together.

[0071] "AAA" is the abbreviation for "Amino Acid Attached."

[0072] "AG" is an abbreviation for "attachment group."

[0073] "Asp" is the abbreviation for aspartic acid.

[0074] “AuNPs” is the abbreviation of “gold nanoparticles”.

[0075] "Cys" is the abbreviation for cysteine.

[0076] "CMD" is the abbreviation for carboxymethyldextrose.

[0077] "Da" is the abbreviation for diazonium salt.

[0078] "DIPEA" is the abbreviation for diisopropylethylamine.

[0079] "DMF" is the abbreviation of "dimethylformamide".

[0080] "DMSO" is the abbreviation of "dimethyl sulfoxide".

[0081] "EDC" is the abbreviation for N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride.

[0082] "Fmoc" is the abbreviation of "9-fluorenylmethyloxycarbonyl chloride".

[0083] “fmoc-Glu-OH” is the abbreviation of “fmoc-L-glutamic acid”.

[0084] "Glu" is the abbreviation for glutamate.

[0085] "Gly" is the abbreviation for glycine.

[0086] "HAA" is the abbreviation for "head amino acid".

[0087] “HATU” is the abbreviation of “(1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate,orhexafluorophosphate azabenzotriazole tetramethyl uronium)”.

[0088] "HG" is the abbreviation for "head group".

[0089] "HIS" is the abbreviation for histidine.

[0090] "HM" is the abbreviation for "hydrophilic moiety".

[0091] "HOBT" is the abbreviation of "hydroxybenzotriazole".

[0092] "IAA" is the abbreviation for iodoacetic acid.

[0093] "IMAC" is an abbreviation for ion metal affinity chromatography.

[0094] "LM" is the abbreviation for "lipophilic moiety".

[0095] "LSPR" is the abbreviation for "Localized Surface Plasmon Resonance".

[0096] "Met" is the abbreviation for methionine.

[0097] “NPs” is the abbreviation for “nanoparticles”.

[0098] "NPC" is the abbreviation for "NH2-PEG-COOH" or "amine-PEG-carboxyl".

[0099] "NR" is the abbreviation of "nitrogen-containing functional group".

[0100] "NSB" is the abbreviation for "non-specific binding".

[0101] "NTA" is the abbreviation for nitrilotriacetic acid.

[0102] "Oac" is the abbreviation of acetyl functional group.

[0103] "PAH" is an abbreviation for polyelectrolyte poly(allylaminehydrochloride).

[0104] "PBS" is the abbreviation for "phosphate buffered saline".

[0105] "PE" is the abbreviation of polyelectrolyte.

[0106] "PEG" is the abbreviation for "polyethylene glycol".

[0107] "Pip" is the abbreviation of piperidine.

[0108] "RA" is the abbreviation for "reagent alcohol".

[0109] "SAA" is the abbreviation for "spacer amino acid".

[0110] "SG" is the abbreviation for "spacer group".

[0111] "SPR" is the abbreviation of "surface plasmon resonance".

[0112] “SR” is the abbreviation for “sulfur-containing functional group”.

[0113] "tBu" is an abbreviation for the tert-butyl functional group.

[0114] "TIS" is the abbreviation of triisopropylsilane.

[0115] "TFA" is the abbreviation for trifluoroacetic acid.

[0116] "Trt" is an abbreviation for a trityl functional group.

[0117] "Amino" refers to any primary, secondary, tertiary or quaternary amine functional group.

[0118] "Analyte" refers to the chemical substance of interest that binds to the ligand and this binding is detected by SPR or LSPR.

[0119] An "anchor site" refers to the location on a chemical chain (eg, a peptide) that is attached to a (eg, gold) surface.

[0120] "Attachment amino acid" refers to any natural or custom synthesized amino acid having one or more functional groups that can serve as an attachment site in a linker.

[0121] "Attachment group" refers to any natural or custom synthesized molecule having one or more functional groups that can serve as an attachment site in a linker.

[0122] "Attachment site" refers to the position on a (eg, peptide) chain (eg, carboxylic acid) to which a ligand is coupled.

[0123] "Diazonium salt" is R-N2 + The chemical part of the form.

[0124] "Head" refers to the anchoring point (eg, thiol) of a linker (eg, peptide chain) that provides a tunable method of anchoring the SAM to a substrate.

[0125] "Head amino acid" refers to any natural or custom synthesized amino acid that serves as an anchor point in the head of a linker.

[0126] "Head group" refers to a molecule that serves as an anchoring point (eg, a thiol) for a linker chain, providing a tunable method of anchoring the SAM to a substrate.

[0127] "Ligand" refers to a chemical moiety that can be coupled to an attachment site and used to bind an analyte. A ligand can be, for example, any binding agent, such as an antibody, aptamer, polymer, DNA or other capture molecule that has affinity for an analyte.

[0128] "Linker" refers to a customizable or tunable molecular chain that can form a self-assembled monolayer (SAM).

[0129] "Linker entity" refers to the portion in the middle of a chemical (eg, peptide) chain that can be adjusted in length, tailored to steric considerations, and adjustable in density of attachment sites.

[0130] "Nanoparticles" refer to particles of varying sizes and shapes, ranging from about 1 nm to 1000 nm, with various area to volume ratios.

[0131] "Metal layer" refers to a thin metal (eg, gold) surface or metal (eg, gold) nanoparticles on a SPR or LSPR sensor substrate.

[0132] "NH2-PEG-COOH" refers to a heterobifunctional PEG polymer having an amino group at one end and a carboxylic acid functional group at the other end.

[0133] "Nitrogen-containing functional group" refers to any primary, secondary, tertiary or quaternary amine or amino group.

[0134] A "peptide spacer" refers to an amino acid sequence (e.g., glycine) that will serve as a spacer between active amino acids with additional carboxylic acid functions. The number of repeating units in the peptide spacer structure varies depending on the space required between the active amino acids. The type of building blocks in the peptide spacer structure can vary depending on the desired hydrophilicity. Peptide spacers can be made by repeating the same unit (e.g., several glycine units) or by combining different building blocks.

[0135] "Polyalkylene glycol" or "PAG" refers to a substituted or unsubstituted linear or branched carbon chain incorporating one or more alkylene glycol moieties (i.e., oxyalkylene moieties), and optionally incorporating one or more additional moieties selected from the group consisting of -S-, -O-, -N-, and -C(O)-. Examples include polyethylene glycol (PEG), polyoxyethylene (POE), polypropylene glycol (PPG), polybutylene glycol (PBG), amine-PEG-carboxyl (NPC), and combinations thereof (e.g., a linear or branched polymer comprising a combination of two or more different PAG subunits, such as two or more different PAG units selected from PEG, PPG, PBG, and NPC subunits).

[0136] “Sensor” refers to the combination of “sensor substrate” and “metal layer” for SPR and LSPR spectroscopy.

[0137] "Sensor substrate" refers to the silicon dioxide containing layer (eg, glass) to which the remainder of the SPR and LSPR sensors are affixed.

[0138] "Spacer" refers to a chemical species located within the body of a linker that is used to extend or shorten a chemical chain (eg, a peptide).

[0139] "Spacer amino acid" refers to any natural or custom synthesized amino acid that is used as a spacer in a linker.

[0140] "Spacer group" refers to any natural or synthetic molecule that serves as a spacer in a linker.

[0141] "Sulfur-containing functional group" refers to any sulfur-containing molecule.

[0142] NTA linker:

[0143] The synthesis of NTA linkers can be challenging due to their versatility and the need for specific spatial orientations to provide effective and stable chelation properties. Despite this complexity, we report here a robust synthetic method for producing NTA linkers with unlimited structural flexibility in the solid phase. The flexibility of this method allows us to synthesize one or more NTA functional groups that are combined with other different functional groups and spacers to provide the desired biochemical properties. One end of the linker can be chemically adsorbed on a gold surface, for example through a thiol or amino group. The distal end or head of the linker is one or more NTA groups. Between these ends, there may be a variety of different spacer groups, ranging from one or more hydrophobic -CH2- sequences to one or more hydrophilic PEG chains, both with adjustable number of units.

[0144] In addition, two or more NTA functional groups may be present on a single linker molecule, where the lengths of the individual NTA branches may be equal or asymmetric (having arms of unequal lengths). The latter may be important when an immobilized protein is large in size and immobilization is limited by steric hindrance. This type of linker allows for varying degrees of immobilization to achieve maximum efficiency over a range of decay lengths.

[0145] SPR sensor:

[0146] In some embodiments, Figure 1As shown, the SPR sensor component 100 is composed of an SPR sensor 118, which has a self-assembled monolayer (SAM) of a chemical linker 120, which can be combined with a ligand 114 that captures an analyte molecule 116. The SPR sensor 118 is composed of a substrate 102 containing silicon dioxide functionalized with a polyelectrolyte 104. In some embodiments, the substrate can be selected from a substrate containing silicon dioxide, a glass substrate, a polystyrene substrate, and an agarose substrate. In some embodiments, the substrate 202 containing silicon dioxide can be a silicon wafer, a glass slide, a polystyrene bead, a controllable pore glass bead, a mixed controllable pore glass bead, an agarose bead, a microbead and a microsphere. It will be understood by those skilled in the art that many other substrates containing silicon dioxide can be used. In some embodiments, the polyelectrolyte 104 changes the surface charge of the substrate 102 containing silicon dioxide, which allows various metals with the same charge as the substrate 102 containing silicon dioxide to bind. In some embodiments, the functionalized silica substrate 104 of the SPR sensor 118 is coated with a thin metal layer 106. The thin metal layer 106 forms the SPR sensor 118 together with the silicon dioxide-containing substrate 102 functionalized with the polyelectrolyte 104. In another embodiment, the thin metal layer 106 is coated with a chemical layer 120, which is composed of a self-assembled monolayer (SAM) of peptide linkers. In some cases, the thin metal layer 106 may include metal nanoparticles. The metal nanoparticles may be configured to generate an optical signal.

[0147] In some embodiments, the SPR sensor chip 118 can be a transparent glass substrate, for example, coated with the remaining components of an SPR sensor. In some embodiments, the transparent glass substrate 102 is functionalized with a polyelectrolyte 104 to allow the metal layer 106 to be electrostatically attached to the sensor substrate. In another embodiment, the polyelectrolyte 104 is poly(allylamine hydrochloride) (PAH). PAH can be purchased from Sigma-Aldrich (Millipore, St. Louis, Missouri, USA) as an example. In another embodiment, the SPR layer 106 can be, for example, a gold layer 106. The gold layer 106 can be chemically modified with a linker 120 so that one of the binding partners, such as a ligand 114, can be fixed. The components of the linker 120 are described below. In some embodiments, the thickness of the gold layer 106 can be about 1 nm to about 1000 nm. For example, gold-coated transparent glass slides can be purchased from GE Healthcare (Uppsala, Sweden).

[0148] LSPR sensor:

[0149] In some embodiments, Figure 2 As shown, the LSPR sensor system 200 is composed of an LSPR sensor 218, which has a self-assembled monolayer (SAM) of a chemical linker 220, which can be combined with a ligand 214 that captures an analyte molecule 216. The LSPR sensor 218 is composed of a substrate 202 containing silicon dioxide functionalized with a polyelectrolyte 204. In some embodiments, the substrate 202 can be selected from a substrate containing silicon dioxide, a glass substrate, a polystyrene substrate, and an agarose substrate. In some embodiments, the substrate 202 containing silicon dioxide can be a silicon wafer, a glass slide, a polystyrene bead, a controllable pore glass bead, a mixed controllable pore glass bead, an agarose bead, a microbead, and a microsphere. It will be understood by those skilled in the art that many other substrates containing silicon dioxide can be used. In some embodiments, the polyelectrolyte 204 changes the surface charge of the substrate 202 containing silicon dioxide, which allows various metals with the same charge as the substrate 102 containing silicon dioxide to bind. In some embodiments, the functionalized silica substrate 204 of the LSPR sensor 218 is coated with adsorbed metal nanoparticles 206. The layer of adsorbed metal nanoparticles 206 together with the silica-containing substrate 202 functionalized with the polyelectrolyte 204 forms the LSPR sensor 218. In another embodiment, the metal nanoparticles 206 are coated with a chemical layer 220 consisting of a SAM of a peptide linker.

[0150] In some embodiments, the LSPR sensor chip 218 may be a transparent glass substrate, for example, coated with the remaining components of an SPR sensor. In some embodiments, the transparent glass substrate 202 is functionalized with a polyelectrolyte 204 to allow the metal nanoparticles to be electrostatically attached to the sensor substrate. In another embodiment, the polyelectrolyte 104 is poly(allylamine hydrochloride) (poly(allylamine hydrochloride, PAH). In another embodiment, the metal nanoparticles 206 may be gold nanoparticles 206. The gold nanoparticles 206 may be chemically modified with a linker 220 so as to be able to immobilize one of the binding partners, such as a ligand 214. The components of the linkers 120, 220 are described below. In some embodiments, the size of the metal nanoparticles may be between about 1 nm and 1000 nm, with various area to volume ratios. The gold nanoparticles may be purchased commercially, for example from Sigma-Aldrich (Millipore, St. Louis, MO) or NanoComposix (San Diego, CA, USA).

[0151] Compositions of metal layers and metal nanoparticles that can be used for SPR and LSPR include gold, silver, platinum, gold-plated silver, silver-plated gold, combinations of these metals, and the like. The shapes of the nanoparticles used can also vary. Useful nanoparticle shapes include, but are not limited to, rods, stars, sea urchins, decahedrons, hexagons, triangles, shells, prisms, platelets, spheres, rice grains, plates, cubes, cages, and bipyramids.

[0152] Connector:

[0153] The linker of the present disclosure generally includes a head (or "anchoring site") 108 for coupling to an SPR or LSPR substrate and a spacer 110. The linker 120 includes one or more attachment sites 112 located at the distal end or terminal of the spacer 110 (or "body"), which are coupled to a ligand 114. The distal end may represent the end of the spacer or a position away from the substrate surface or the sensor surface. In some embodiments, the linker 120 may include a matrix. In some embodiments, the linker 120 may be disposed on a portion of the surface of the metal nanoparticle 106. Although it can be understood that a variety of variations and alternative embodiments can be conceived or constructed by those skilled in the art based on the teachings of the present disclosure, the linker-ligand structure can be simply described as follows:

[0154] Substrate 106 —head 108 —spacer 110 —attachment 112 —ligand 114 .

[0155] In operation, the ligand can be coupled to the analyte:

[0156] Substrate 106 —head 108 —spacer 110 —attachment 112 —ligand 114 —analyte 116 .

[0157] The resulting combination can be detected using SPR or LSPR spectroscopy.

[0158] It should be understood that within the scope of the present disclosure, there may be a combination of various chemicals to optimize the length, spatial considerations, hydrophobicity / hydrophilicity, lipophilicity / lipophobicity, and density of the attachment site 112 in the linker. In some embodiments, the arrangement of chemicals in the adjustable linker 120 can be represented by the following schematic diagram:

[0159] HG-SG-AG;

[0160] Wherein "HG" is a "head group", "SG" is a "spacer group", and "AG" is an "attachment group". In another embodiment, there may be a plurality of head 108 groups attached in a continuous manner (e.g., linearly) or in a branched manner in the adjustable linker 120. In another embodiment, there may be a plurality of spacer 110 groups attached in a continuous manner or in a branched manner in the adjustable linker 120. In another embodiment, both the head 108 and spacer 110 groups may be arranged in a linear or branched arrangement combination. In another embodiment, there may be a plurality of -SG-AG repeating units in the adjustable linker. Such embodiments may be represented by the following schematic diagrams:

[0161] HG X —SG Y —AG A ;and

[0162] HG X [—SG Y —AG A ]Z;

[0163] wherein the arrangement of HG, SG and AG may be a linear or branched arrangement; and wherein there is always an appropriate number of bonds between the chemical groups; wherein X represents the number of head 108 groups in the head 108 region of the linker 120 in a continuous arrangement or any other arrangement such as a branch; and wherein Y represents the number of spacer 110 groups in the spacer 110 region of the linker 120 in a continuous arrangement or any other arrangement such as a branch; and wherein A represents the number of attachment groups 112 in the spacer region 110 of the linker 120 in a continuous arrangement or any other arrangement such as a branch; and wherein Z represents a repeating -SG in the spacer 110 region of the linker 120 in a continuous arrangement or any other arrangement such as a branch Y -AG A and wherein X ranges from 1 to 20, or 1 to 8, or 1 to 6, or 1 to 4; and Y ranges from 0 to 50, or 0 to 40, or 0 to 30, or 0 to 20, or 0 to 10, or 0 to 5; and A ranges from 1 to 50, or 1 to 40, or 1 to 30, or 1 to 20, or 1 to 10, or 1 to 5; and Z can range from 1 to 10, or 2 to 8, or 2 to 6, or 2 to 4. In some embodiments, the linker can be a matrix of a biopolymer, such as a polysaccharide, a polysaccharide derivative, a polymer, a functionalized polymer, a protein, or a combination thereof.

[0164] In some embodiments, the chemical substances in the linker 120 are arranged in the following order: HG—SG—AG—SG—AG—SG—AG—SG—AG. In this embodiment, for the sake of clarity, Z is taken as an example of 4. In some embodiments, the linker head 108, the spacer 110, and the attachment 112 group can all be composed of peptides. In this embodiment, the linker is a tunable peptide linker. In some embodiments, the linker head 108, the spacer 110, and the attachment 112 group can each be composed of a carbohydrate.

[0165] Connector-Head

[0166] In some embodiments, Figure 1 As shown, the linker head 108 or linker "anchor point" can be composed of any chemical functional group that binds to the substrate 106. In another embodiment, the linker head 108 can be composed of a sulfur-containing chemical group. In another embodiment, the linker head 108 can be composed of a sulfide (RS-R') chemical group. In another embodiment, the linker head 108 can be composed of a thiol (-SH) chemical group. In another embodiment, the linker head 108 can be composed of a disulfide (-S-SH) chemical group. In another embodiment, the linker head 108 can be composed of any functional group having more than two sulfurs. In another embodiment, the linker head 108 can be composed of any Group VI chalcogen.

[0167] In another embodiment, the linker head 108 may be composed of at least one methionine amino acid group, which includes a sulfide group. In another embodiment, the linker head 108 may be composed of at least one cysteine ​​amino acid group, which includes a thiol group. Binding occurs spontaneously between a gold substrate 106 and the thiol functional group. Binding occurs spontaneously between a gold substrate 106 and the sulfide functional group.

[0168] In another embodiment, the linker head 108 may be composed of at least one thiol that is bound to a sugar. In another embodiment, the linker head 108 may be composed of at least one thioglucose. The binding occurs spontaneously between the gold substrate 106 (e.g., an Au NP) and the sulfide functional group, thereby forming a covalent bond.

[0169] In another embodiment, the linker head 108 may be composed of a carbon-containing chemical group. In another embodiment, the linker head 108 may be composed of a diazonium salt. The bonding occurs spontaneously between a gold substrate 106 and the diazonium functional group.

[0170] In another embodiment, the linker head 108 may consist of a nitrogen-containing chemical group. In another embodiment, the linker head 108 may consist of an amino group. In another embodiment, the linker head 108 may consist of a primary amine, secondary amine, tertiary amine, or quaternary amine group. Binding occurs spontaneously between a gold surface and the amino functional group.

[0171] In another embodiment, the linker head 108 may be composed of any chemical functional group that readily binds to any metal (eg, gold) surface 106 .

[0172] In some embodiments, HG is an amino acid. In this embodiment, HG is a head amino acid (HAA) composed of any natural or synthetic amino acid. The arrangement can be more generally shown by the following schematic diagram:

[0173] HAA X —SG Y —AG A ;and

[0174] HAA X [—SG Y —AG A ] Z ;

[0175] wherein the arrangement of HAA, SG and AG may be linear or branched; and wherein there is always an appropriate number of bonds between the chemical groups; and wherein X represents the number of HAA groups in a continuous arrangement or any other arrangement such as a branch in the head 108 region of the linker 120; and wherein Y represents the number of spacer 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120; and wherein A represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein Z represents a repeating -SG in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120 Y -AG A The number of groups; and wherein X ranges from 1 to 20, or from 2 to 8, or from 2 to 6, or from 2 to 4, and Y ranges from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5, and A ranges from 1 to 50, or from 1 to 40, or from 1 to 30, or from 1 to 20, or from 1 to 10, or from 1 to 5; and Z may range from 1 to 10, or from 2 to 8, or from 2 to 6, or from 2 to 4.

[0176] In another embodiment, the linker head 108 is at least a cysteine ​​amino acid group, which can be represented by the following schematic diagram:

[0177] Cys X —SG Y —AG A ;and

[0178] Cys X [—SG Y —AG A ] Z ;

[0179] Wherein X represents the number of Cys groups in the linker head 108. In one embodiment, the number of cysteine ​​amino acids in the linker head 108 ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of cysteine ​​amino acids at the linker head is 1.

[0180] In one embodiment, the head of the linker is at least one methionine amino acid, which can be represented by the following schematic diagram:

[0181] Met X —SG Y —AG A ;and

[0182] Met X [—SG Y —AG A ] Z ;

[0183] Wherein X is the number of Met groups in the linker head. In one embodiment, the number of methionine amino acids in the linker head ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of methionine amino acids at the linker head is 1.

[0184] In one embodiment, the head of the linker is composed of at least one sulfur-containing functional group "SR", which can be represented by the following schematic diagram:

[0185] SR X —SG Y —AG A ;and

[0186] SR X [—SG Y —AG A ] Z ;

[0187] Wherein X represents the number of sulfur-containing "SR" functional groups in the linker head. Sulfur-containing functional groups "SR" include any naturally occurring or synthetic molecules that contain one or more sulfur elements in a linear or branched structure, such as disulfides, dithiocarbamates, dithiocarbamic acids, thiocarboxylic acids (thioacids), thiocarboxylic acids, or anions of any of these molecules. In one embodiment, the number of sulfur-containing functional groups in the linker head ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of sulfur-containing functional groups at the linker head is 1.

[0188] In one embodiment, the head of the linker is composed of at least one diazo functional group, which can be represented by the following schematic diagram:

[0189] Da X —SG Y —AG A ;and

[0190] Da X [—SG Y —AG A ] Z ;

[0191] Wherein X represents the number of diazo functional groups in the linker head. In one embodiment, the number of diazo functional groups in the linker head ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of diazo functional groups at the linker head is 1.

[0192] In another embodiment, the head of the linker is composed of at least one amino functional group, including primary amine, secondary amine, tertiary amine and quaternary amine groups "NR", which can be represented by the following schematic diagram:

[0193] NR X —SG Y —AG A ;and

[0194] NR X [—SG Y —AG A ] Z ;

[0195] Wherein X represents the number of primary, secondary, tertiary or quaternary amino "NR" functional groups in the linker head. In one embodiment, the number of amino functional groups in the linker head ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of amino functional groups at the linker head is 1.

[0196] The thiol (-SH) functional group in cysteine, the sulfide (RS-R') functional group in methionine, and the diazo functional group (R-N2+ ) spontaneously binds to a gold substrate or nanoparticle. Increasing the number of thiol functional groups by increasing the number of cysteine ​​in the tunable peptide linker head X can result in a stronger connection or anchoring of the linker head to gold. Increasing the number of sulfide functional groups by increasing the number of methionine in the tunable peptide linker head X can result in a stronger connection of the linker head to gold. Increasing the number of other sulfur-containing functional groups in the tunable peptide linker head can result in a stronger binding force between the linker head and gold. Increasing the number of diazo functional groups in the tunable peptide linker head can result in a stronger binding force between the linker head and gold. Increasing the number of amino functional groups in the tunable peptide linker head can result in a stronger binding force between the linker head and gold. Increasing the number of carbon-containing functional groups in the tunable peptide linker head can result in a stronger binding force between the linker head and gold. In one embodiment of the present disclosure, therefore, the stability of the peptide linker SAM attached to the metal surface can be adjusted by selecting the number of head functional groups that bind to the (e.g., gold) substrate.

[0197] In some embodiments, thiols (-SH), sulfides (RS-R'), and diazos (R-N2 + ) functional groups spontaneously bind to metal substrates (e.g., gold substrates) or nanoparticles (e.g., gold nanoparticles). Increasing the number of thiol, sulfide, or diazo groups of headsaccharides (HS) can increase the density of sugars on the surface of metal nanoparticles or substrates.

[0198] Linker-body / spacer:

[0199] The characteristics of the linker "body" 110 or the middle part of the linker can be adjusted according to the length, space considerations and density of the attachment 112 sites of the ligand 114. Although a variety of variations can be understood or constructed by those skilled in the art, the linker body 110 can be configured in a linear (e.g., "straight chain") manner. In addition, the linker body 110 can be configured as one or more branches in the chemical structure. The linker body 110 may include a molecule that acts as a "spacer" 110.

[0200] In some embodiments, a spacer 110 molecule can be any molecule intended to increase or decrease the length of the linker 120. In some embodiments, the spacer 110 can be any molecule selected based on its length. For example, the spacer 110 can be a polymer. In this embodiment, the number of repeating monomer units can be selected to increase or decrease the length of the spacer 110. In another embodiment, the spacer 110 can be a monomer unit of a polymer. Although a variety of variations can be understood or constructed by those skilled in the art, the spacer 110 can be any type of polyalkylene glycol (PAG) or any type of functionalized PAG, such as NH2-PEG-COOH (NPC).

[0201] PAG compounds such as PEG are commercially available from various sources, such as Sigma-Aldrich (Millipore, St. Louis, MO) and BroadPHARM (San Diego, CA). Monodisperse PEG is preferred. In another embodiment, the spacer molecule can be "NH2-PEG-COOH" (NPC), such as commercially available from Sigma-Aldrich (Millipore, St. Louis, MO) and Advanced Biochemicals (Lawrenceville, GA). Monodisperse NPC is preferred.

[0202] In some embodiments, the spacer 110 may be any natural or synthetic amino acid. In this embodiment, the amino acid acting as a spacer 110 may be a "spacer amino acid" (SAA). The number of SAAs linked together may be selected to increase or decrease the length of the spacer 110. In some embodiments, the SAAs may be the same amino acid or a combination of any natural or synthetic amino acids. In another embodiment, the number of SAAs is from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5. In a preferred embodiment, the number of SAAs is 1.

[0203] In some embodiments, the SAA may consist of glycine. In another embodiment, the SAA may consist of phenylalanine. In another embodiment, the SAA may be any amino acid or sequence of two or more amino acids that is used to increase or decrease the length of the linker. In some embodiments, the spacer may consist of repeating units of any of the above molecules. In another embodiment, the spacer or SAA may consist of a combination of various molecules, polymers, monomers, amino acids or other chemicals, whether naturally occurring, commercially available or synthesized in the laboratory.

[0204] The amino acids used in the linkers of the present disclosure can be purchased from commercial suppliers or made manually by solid-phase peptide synthesis (SPPS) as described below or using a peptide synthesis machine. Examples of suitable machines include the CSBio II from CSBio (Menlo Park, CA) or the Biotage (Uppsala, Sweden). Initiator+Alstra TM Peptide Synthesizers. Examples of suppliers that offer custom synthesized peptide chains include Biomatik (Wilmington, DE) and Thermo Fisher Scientific (Waltham, MA).

[0205] In some embodiments, the spacer 110 may be any natural or synthetic carbohydrate. In this embodiment, the carbohydrate acting as a spacer 110 may be a "spacer carbohydrate" (SS). The number of SSs linked together may be selected to increase or decrease the length of the spacer 110. In some embodiments, the SSs may be the same amino acid or a combination of any natural or synthetic amino acids. In another embodiment, the number of SSs is from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5. In some embodiments, the number of SSs is 1. In some embodiments, the number of SSs is 0.

[0206] In some embodiments, the SAA may consist of glycine. In another embodiment, the SAA may consist of phenylalanine. In another embodiment, the SAA may be any amino acid or sequence of two or more amino acids that is used to increase or decrease the length of the linker. In some embodiments, the spacer may consist of repeating units of any of the aforementioned molecules. In another embodiment, the spacer or SAA may consist of various combinations of molecules, polymers, monomers, amino acids, sugars, or other chemicals, whether naturally occurring, commercially available, or synthesized in the laboratory.

[0207] The amino acids used in the linkers of the present disclosure can be purchased from commercial suppliers or made manually by solid-phase peptide synthesis (SPPS) as described below or using a peptide synthesis machine. Examples of suitable machines include the CSBio II from CSBio (Menlo Park, California) or the Biotage (Uppsala, Sweden). Initiator+Alstra TMPeptide Synthesizers. Examples of suppliers that offer custom synthesized peptide chains include Biomatik (Wilmington, Delaware) and Thermo Fisher Scientific (Waltham, Massachusetts).

[0208] The sugars used in the linkers of the present disclosure can be purchased from commercial suppliers. The sugars can be chemically modified as described below.

[0209] In some embodiments, HG and SG are both amino acids. In another embodiment, HG is a head amino acid (HAA) composed of any amino acid, whether natural or synthetic, and SG is a spacer amino acid (SAA) composed of any amino acid, whether natural or synthetic. The arrangement can be more generally shown by the following schematic diagram:

[0210] HAA X —SAA Y —AG A ;and

[0211] HAA X [—SAA Y —AG A ] Z ;

[0212] wherein the arrangement of HAA, SAA and AG can be a linear or branched arrangement; and wherein there is always an appropriate number of bonds between the chemical groups; and wherein X represents the number of HAA groups in a continuous arrangement or any other arrangement such as a branch in the head region of the linker; and wherein Y represents the number of SAA groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker; and wherein A represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein Z represents the number of repeating-SAA groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker Y -AG A The number of groups; and wherein X ranges from 1 to 20, or from 2 to 8, or from 2 to 6, or from 2 to 4; and Y ranges from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5, and A ranges from 1 to 50, or from 1 to 40, or from 1 to 30, or from 1 to 20, or from 1 to 10, or from 1 to 5; and Z may range from 1 to 10, or from 2 to 8, or from 2 to 6, or from 2 to 4.

[0213] In another embodiment, the linker spacer is at least one glycine amino acid group, which can be represented by the following schematic diagram:

[0214] HAA X —Gly Y —AG A ;and

[0215] HAA X [—Gly Y —AG A ] Z ;

[0216] Wherein Y represents the number of glycine groups in the linker body. In one embodiment, the number of glycine amino acids in the linker body ranges from 1 to 20. In a preferred embodiment, the number of glycine amino acids at the linker body is 1.

[0217] In some embodiments, HG, SG and AG are all carbohydrates. In another embodiment, HG is composed of SR 1 NR 1 R 2 , OR 1 , CR 1 The sugars are composed of modified sugars, where R 1 and R 2 are independently hydrogen, halogen, C1-C 10 Alkyl C1-C 10 Alkenyl, C1-C 10 Alkynyl, Nitrile, C1-C 10 Carbon ring, C1-C 10 Aryl, C1-C 10 Heteroaryl, C1-C 10 Heterocycles or combinations thereof. The arrangement can be more generally shown by the following schematic diagram:

[0218] HG X —SG Y —AG A ;and

[0219] HG X [—SG Y —AG A ] Z ;

[0220] wherein the arrangement of HG, SG and AG can be a linear or branched arrangement; and wherein there are an appropriate number of bonds between the chemical groups; and wherein X represents the number of HAA groups in a continuous arrangement or any other arrangement such as a branch in the head region of the linker. Y represents the number of SG groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker. A represents the number of attachment groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker. Z represents the number of repeating -SG groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker. Y -AG A The number of groups. X can range from 1 to 20, 2 to 8, 2 to 6, 2 to 4; and Y can range from 0 to 50, 0 to 40, 0 to 30, 0 to 20, 0 to 10, 0 to 5, and A can range from 1 to 50, 1 to 40, 1 to 30, 1 to 20, 1 to 10, 1 to 5; and Z can range from 1 to 10, or 2 to 8, or 2 to 6, or 2 to 4.

[0221] In another embodiment, the linker spacer is at least one glucose group, which can be represented by the following schematic diagram:

[0222] HG X -[glucose] Y —AG A ;and

[0223] HG X [-[glucose] Y —AG A ] Z ;

[0224] Wherein Y represents the number of glucose groups in the linker body. In some embodiments, the number of glucose groups in the linker body ranges from 1 to 20. In some embodiments, the number of spacer saccharides (SS) at the linker body is 1. In some embodiments, the number of spacer saccharides (SS) at the linker body is 0 (i.e., Y is 0). Each glucose unit can be bonded to another glucose unit by a 1,1-, 1,2-, 1,3-, 1,4-, 1,5- or 1,6-glycosidic bond.

[0225] In another embodiment, HG is a head amino acid (HAA) composed of any natural or synthetic amino acid, and SG is a "polyalkylene glycol" (PAG), such as polyethylene glycol, polypropylene glycol, amine-PEG-carboxyl (NPC), etc., and various combinations of the above substances. The arrangement can be more generally shown by the following schematic diagram:

[0226] HAA X —PAG Y —AG A ;and

[0227] HAA X [—PAG Y —AG A ] Z ;

[0228] wherein the arrangement of HAA, PAG and AG may be a linear or branched arrangement; and wherein there are an appropriate number of bonds between the chemical groups; and wherein X represents the number of HAA groups in a continuous arrangement or any other arrangement such as a branch in the head region of the linker; and wherein Y represents the number of PAG groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker; and wherein A represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein Z represents a number of repeating-PAG groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker. Y -AG A the number of groups; and wherein X ranges from 1 to 20, or from 2 to 8, or from 2 to 6, or from 2 to 4, and Y ranges from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5, and A ranges from 1 to 50, or from 1 to 40, or from 1 to 30, or from 1 to 20, or from 1 to 10, or from 1 to 5; and Z may range from 1 to 10, or from 2 to 8, or from 2 to 6, or from 2 to 4.

[0229] In some embodiments, the number of PAG units in spacer Y ranges from 1 to about 20. In another embodiment, the number of PAG units in spacer Y ranges from about 2 to about 15. In another embodiment, the number of PAG units in spacer Y ranges from about 2 to about 10. In another embodiment, the number of PAG units in spacer Y is about 8. In some embodiments, the PAG units include PEG units, and the number of PEG units in spacer Y ranges from 1 to about 20. In another embodiment, the PAG units include PEG units, and the number of PEG units in spacer Y ranges from about 2 to about 15. In another embodiment, the PAG units include PEG units, and the number of PEG units in spacer Y ranges from about 2 to about 10. In another embodiment, the PAG units include PEG units, and the number of PEG units in spacer Y ranges from about 2 to about 10. The number of NPC units in spacer Y is about 8. In a preferred embodiment, the PAG is NPC. In some embodiments, the number of NPC units in spacer Y ranges from 1 to about 20. In another embodiment, the number of NPC units in spacer Y ranges from about 2 to about 15. In another embodiment, the number of NPC units in spacer Y ranges from about 2 to about 10. In another embodiment, the number of NPC units in spacer Y is about 8. In another preferred embodiment, the PAG is NPC and Y is 8.

[0230] In one embodiment of the present disclosure, the length of the linker is adjustable. In some embodiments, the length of the peptide linker can be adjusted by changing the number and type of spacer groups.

[0231] In another embodiment of the present disclosure, the head group (HG) is a functional group composed of any group of sugars, whether natural or synthetic. In some embodiments, HG can be a sugar. In some embodiments, the sugar can be a polysaccharide. In some further embodiments, the sugar can be a disaccharide. In some cases, the sugar can include carboxymethyl glucose, glucose, amylose, galactose, or a combination thereof. In some embodiments, the sugar can be thiolated. In some cases, the head group can include a disaccharide.

[0232] Linker-Attachment Site:

[0233] Linkers 120 may also include molecules or functional groups located at the distal end of the linear or branched molecular chain linker 120 that serve as attachment sites 112 for ligands. Linkers 120 may use one or more attachment sites 112 to couple to ligand 114 functional groups.

[0234] In some embodiments, the linker attachment site 112 is a molecule consisting of any chemical functional group that binds to the ligand 114. In some embodiments, the linker attachment site 112 includes any chemical functional group that is connected to the previous molecule in the linker chemical chain. In some embodiments, the linker attachment site 112 includes any chemical functional group that is connected to the subsequent molecule in the linker 120 chemical chain. In some embodiments, the linker attachment site 112 may further include a metal ion. In some embodiments, the metal ion includes a transition metal ion. In some further embodiments, the transition metal ion includes nickel, iron, cobalt or copper. In some embodiments, the metal ion is selected from the group consisting of nickel, iron, cobalt, copper and calcium. In some cases, the metal ion can be configured to chelate to the aromatic side chain of the protein (e.g., histidine, tyrosine, tryptophan, phenylalanine) and the attachment site 112, such as an attachment site including a carboxylate.

[0235] In some embodiments, there are one or more functional groups at the linker attachment site 112. In a preferred embodiment, the linker attachment site is composed of three functional groups. In a most preferred embodiment, two functional groups at the linker attachment site are used to connect to the previous and subsequent molecules in the chain, and the third functional group is suitable for providing an attachment site 112 for the ligand 114. In a preferred embodiment, the one or more chemical functional groups include a carboxylic acid functional group. In a preferred embodiment, the one or more chemical functional groups include an amino functional group. In some embodiments, the attachment site 112 is an amino acid. In a preferred embodiment, the attachment site 112 is a nitrotriacetic acid (NTA) moiety. If the attachment site is located on an amino acid, this amino acid is called an "attachment amino acid" (AAA). Examples of attachment amino acids (AAA) that can be used in the linker 120 of the present disclosure include aspartic acid, glutamic acid, any natural or synthetic amino acid with an additional functional group (e.g., lysine with an additional amino group), and mixtures of any of the above. If the attachment site is located on a sugar, the sugar is called an "attachment saccharide" (AS). In some embodiments, any molecule that binds to a ligand 114, such as biotin or trinitroacetic acid, can be attached to the linker body 110 to become an attachment site 112.

[0236] The properties of the spacer 110 molecule can be adjusted to adjust the length of the linker 120 and the density of the attachment sites 112. The length of the linker 120 and the density of the attachment sites 112 can be adjusted according to the spatial considerations of the ligand 114 and the analyte. In some embodiments, the attachment amino acid (AAA) can be aspartic acid, which has a carbon spacer between the attachment functional groups. In another embodiment, AAA can be glutamic acid, which has two carbon spacers between the attachment functional groups. In another embodiment, AAA can be lysine, which has four carbon spacers between the attachment functional groups. In another embodiment, the spacer can be a mixture of AAA. In another embodiment, the number of AAA and the specific sequence of AAA can be selected to adjust the length of the linker 120 and adjust the density of the attachment sites 112. Figure 3 illustrates an exemplary SPR or LSPR tunable linker molecule, whose density of attachment sites decreases or increases (e.g., -COOH), while the number of spacer molecules increases or decreases conversely, and the spacer molecules are represented by wavy lines. As shown in Figure 3, establishing a linker 120 with more aspartic acid moieties may result in a higher density of attachment sites 302, while establishing a linker with more lysine moieties may result in a lower density of attachment sites 304 simply because the increased number of -CH2- units results in a greater distance between subsequent carboxylic acid (for example) attachment moieties.

[0237] Increasing the number of ligand 114 moieties coupled to linker 120 can increase the number of binding sites for capturing molecules of analyte 116. Increasing the number of captured analyte 116 molecules can improve SPR and LSPR signals.

[0238] In some embodiments, the attachment saccharide (AS) may be a carboxymethyl dextrose (CMD) having a carboxylic acid group. In another embodiment, AS may be a carboxymethyl dextrose (CMD) modified with at least one multidentate group. In some embodiments, the multidentate group includes one or more carboxylic acid groups. In some embodiments, the multidentate group includes nitrilotriacetic acid (NTA), tris-(2-aminoethyl)amine, or a combination thereof. In some embodiments, the multidentate group is a tridentate group. In some embodiments, the multidentate group is nitrilotriacetic acid (NTA), which has three carboxylic acid groups. In another embodiment, the spacer may be a mixture of saccharides. In another embodiment, the number of ASs may be selected to adjust the length of the linker 120, and to adjust the density of the attachment sites 112, such as the density of available NTA sites. Figure 3BIllustrated are exemplary SPR or LSPR tunable linker molecules with a decreased or increased density of attachment sites (e.g., -COOH) and a conversely increased or decreased number of spacer molecules, represented as hexagons (e.g., for a polysaccharide backbone). Figure 3B As shown, creating a linker 120 with more -COOH moieties (e.g., by incorporating NTA) can create a higher density of attachment sites 302. Figure 3C As shown, a linker 120 having more carboxylate moieties bound to sugars (hexagons) is established, and these sugars (hexagons) are bound to other sugar chains through glycosidic bonds, which can establish a higher density of attachment sites for attaching ligands. In some embodiments, the linker (e.g., a matrix) may include attachment sites (e.g., multi-dentate sites) with a density ranging from about 1% to about 100%, about 10% to about 90%, about 20% to about 80%, about 25% to about 75%, about 30% to about 70%, or about 40% to about 60%. In some embodiments, the density of attachment sites may be about 1% to about 100%, about 10% to about 90%, about 20% to about 80%, about 25% to about 75%, about 30% to about 70%, or about 40% to about 60% of the total number of available sites of the linker. In some embodiments, the density of attachment sites is at least about 25% of the volume. In some embodiments, the density of attachment sites is at least about 25% of the total number of available sites. In some embodiments, the density of attachment sites does not exceed about 90%.In some embodiments, the density of attachment sites does not exceed about 90% of the total number of available sites.

[0239] The linker 120 can be selected or designed to avoid non-target molecules in the capture sample, thereby reducing non-specific binding (NSB) noise to a level lower than that of the prior art. Increasing the signal and reducing the noise can improve the signal-to-noise ratio of the SPR and LSPR signals.

[0240] In some embodiments, HG, SG, and AG are amino acids. In another embodiment, HG is a head amino acid (HAA) composed of any amino acid, whether natural or synthetic, SG is a spacer amino acid (SAA) composed of any amino acid, whether natural or synthetic, and AG is an attachment amino acid (AAA) composed of any amino acid, whether natural or synthetic. The preferred arrangement can be shown by the following schematic diagram: HAA—SAA—AAA—SAA—AAA—SAA—AAA—SAA—AAA—SAA—AAA. Other embodiments can be more generally shown by the following schematic diagram:

[0241] HAAX —SAA Y —AAA A ;and

[0242] HAA X [—SAA Y —AAA A ] Z ;

[0243] wherein the arrangement of HAA, SG and AG can be a linear or branched arrangement; and there is always an appropriate number of bonds between the chemical groups; and X represents the number of HAA groups in a continuous arrangement or any other arrangement such as a branch in the head region of the linker; and Y represents the number of spacer groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker; and A represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein Z represents the number of repeating-SAA in a continuous arrangement or any other arrangement such as a branch in the body region of the linker Y -AAA A The number of groups wherein X ranges from 1 to 20, or from 2 to 8, or from 2 to 6, or from 2 to 4, and Y ranges from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5, and A ranges from 1 to 50, or from 1 to 40, or from 1 to 30, or from 1 to 20, or from 1 to 10, or from 1 to 5; and Z may range from 1 to 10, or from 2 to 8, or from 2 to 6, or from 2 to 4.

[0244] Examples of amino acids that can be used for the attachment site of the adjustable peptide linker include: aspartic acid, glutamic acid, any natural or custom synthesized amino acid with an additional functional group, such as lysine with an additional amino group, and mixtures of any of the above. The arrangement can be shown by the following schematic diagram:

[0245] HAA X —SAA Y —Asp A ;

[0246] HAA X —SAA Y —Glu A ;

[0247] HAA X —SAA Y —Lys A ;

[0248] HAA X [—SAA Y —Asp A ]Z ;

[0249] HAA X [—SAA Y —Glu A ] Z ;and

[0250] HAA X [—SAA Y —Lys A ] Z ;

[0251] wherein A represents the number of Asp, Gly or Lys groups in the linker attachment site; and wherein Z represents repeated -SAA in the linker attachment site. Y -Asp A In one embodiment, the number of aspartic acid in the linker body ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of aspartic acid at the linker body is 1. In one embodiment, the number of glutamic acid in the linker body ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of glutamic acid at the linker body is 1. In one embodiment, the number of lysine in the linker body ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of lysine at the linker body is 1. In a preferred embodiment, at the attachment site (

[0252] In some embodiments, selecting Glu or Asp as AAA can make the linker very hydrophilic. The state of the art uses hydrophobic chemical chains to bind to ligands. The hydrophobic chemical chains bind non-specifically (NSB) to abnormal molecules in the analyte solution, resulting in instrument noise. Selecting a hydrophilic AAA in the linker, such as glutamic acid and aspartic acid, can reduce the instrument noise below current levels. Reducing instrument noise can improve the signal-to-noise ratio in the analysis.

[0253] In some embodiments, HG, SG, and AG are saccharides. In another embodiment, HG is a head saccharide (HS) composed of any saccharide, whether natural or synthetic, SG is a spacer saccharide (SS) composed of any saccharide, whether natural or synthetic, and AG is an attachment saccharide (AS) composed of any saccharide, whether natural or synthetic. A preferred arrangement can be shown by the following schematic diagram: HS-SS-AS-SS-AS-SS-AS-SS-AS. Other embodiments can be shown more generally by the following schematic diagram:

[0254] HS X —SS Y —AS A ;and

[0255] HS X [—SS Y —AS A ] Z ;

[0256] wherein the arrangement of HS, SS and AS may be a linear or branched arrangement; and wherein there are an appropriate number of bonds between the chemical groups; and wherein X represents the number of HS groups in a continuous arrangement or any other arrangement such as a branch in the head region of the linker; and wherein Y represents the number of spacer groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker; and wherein A represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein Z represents a number of repeating-SS groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker Y -AS A The number of groups wherein X ranges from 1 to 20, or from 2 to 8, or from 2 to 6, or from 2 to 4, and Y ranges from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5, and A ranges from 1 to 50, or from 1 to 40, or from 1 to 30, or from 1 to 20, or from 1 to 10, or from 1 to 5; and Z may range from 1 to 10, or from 2 to 8, or from 2 to 6, or from 2 to 4.

[0257] Examples of carbohydrates that can be used for the adjustable linker attachment site include glucose, amylose, galactose, any natural or custom synthesized carbohydrate with an additional functional group (e.g., glucose with a thiol group), and mixtures of any of the above. The arrangement can be shown by the following schematic diagram:

[0258] HS X —SS Y —AS A ;

[0259] wherein A represents the number of carboxylate or amine groups in the linker attachment site; wherein Z represents the number of repeated -SS in the linker attachment site. Y -AS AIn one embodiment, the number of carboxylate or amine groups in the linker body ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of aspartic acid at the linker body is 1. In one embodiment, the number of carboxylate groups in the linker body ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of carboxylate groups at the linker body is 1. In one embodiment, the number of amine groups in the linker body ranges from 1 to 20, or from 1 to 10, or from 1 to 5. In a preferred embodiment, the number of amine groups at the linker body is 1. In a preferred embodiment, the carbohydrate at the attachment site (AS) is glucose. In some embodiments, the carbohydrate at AS is substituted with R', -C(O)-R' or -C(O)NR', ​​wherein R' is hydrogen, C1-C 10 Alkyl, C1-C 10 Alkenyl, C1-C 10 Alkynyl, C1-C 10 Carbon ring, C1-C 10 Heterocyclic, C1-C 10 Aryl, C1-C 10 Each of HS, SS or AS can be linked via a 1,2-, 1,3-, 1,4-, 1,5-, or 1,6-glycosidic bond, or a combination thereof.

[0260] In some embodiments, selecting Glu or Asp as AAA can make the linker very hydrophilic. Prior art uses hydrophobic chemical chains to bind to ligands. Hydrophobic chemical chains bind non-specifically (NSB) to abnormal molecules in the analyte solution, resulting in instrument noise. Selecting a hydrophilic AAA in the linker, such as glutamic acid and aspartic acid, can reduce instrument noise below current levels. Reducing instrument noise can improve the signal-to-noise ratio in the analysis.

[0261] In some embodiments, one or more attachment amino acid (AAA) or attachment saccharide (AS) sites located in the linker body may include any chemical functional group that can be used for coupling with a ligand. In some embodiments of the present disclosure, a carboxylic acid functional group (e.g., -COOH) may be used as an attachment site. In some embodiments, the carboxylic acid functional group may be derived from a nitrilotriacetic acid (NTA) functional group. In some embodiments, the AAA or AS site may include an amino group, such as an amino group derived from tris-(2-aminoethyl)amine. Although it should be understood that a variety of chemical reactions may occur within the scope of the present disclosure, the carboxylic acid functional group may be dehydrated, for example, using a functional group on the ligand to form a bond. In another embodiment, the attachment site may be an amino functional group. In one example, the amino functional group may be dehydrated, for example, using a functional group on the ligand to form a bond. In another embodiment, the attachment site may be a biotin molecule. In another embodiment, the attachment site may be one or more nitrilotriacetic acid (NTA) molecules. In another embodiment, the attachment site may be any functional group that can be chemically converted to a carboxylic acid functional group. In another embodiment, the attachment site may be any functional group that can be chemically converted to an amino functional group. In another embodiment, the attachment site may be any functional group that can be chemically converted to a nitrilotriacetic acid (NTA) molecule. In another embodiment, the attachment site may be from any natural or synthetic amino acid, carbohydrate, or other moiety with a functional group that can bind to a ligand by itself, or can be chemically modified to bind to a ligand.

[0262] In some embodiments, the attachment site may further include a cation. In some embodiments, the cation is a metal ion. Attachment site 112 includes a carboxylate or other chemical group that can chelate to the metal ion. In some cases, the metal ion includes a transition metal ion. In some embodiments, the transition metal ion includes nickel, iron, cobalt, copper, or zinc. In some embodiments, the metal ion is selected from the group consisting of nickel, iron, cobalt, copper, zinc, calcium, sodium, magnesium, and combinations thereof. In some embodiments, the metal ion is chelated to attachment site 112 and ligand 114.

[0263] 3, the number of attachment sites (e.g., carboxylic acid or NTA) and spacer (e.g., NPC) units can be selected to achieve a desired density of attachment sites on the linker. For example, larger ligands may require a lower attachment site density 304, while smaller ligands may support a greater attachment site density 302. Similarly, larger analytes may require a lower ligand density, while smaller analytes may support a greater ligand density.

[0264] In some embodiments, the linker may be a matrix, and the matrix may include a matrix thickness. In some embodiments, the matrix thickness may be about 1 nm to about 100 nm. In some embodiments, the matrix thickness may be about 1 nm to about 100 nm, about 10 nm to about 90 nm, about 20 nm to about 80 nm, about 30 nm to about 70 nm, or about 40 nm to about 60 nm. In some embodiments, the matrix thickness is at least 10 nm. In some embodiments, the matrix thickness is at most 100 nm. In some embodiments, the matrix thickness does not exceed 1000 nm. In some embodiments, the matrix thickness is not less than 1 nm.

[0265] In some cases, as shown by the wavy line 306 in FIG. 3 , fewer PAG or spacer groups and more amino acids (e.g., with a -COOH functional group) or one or more NTA molecules can be used to increase the density of attachment sites, thereby increasing the density of ligands that can bind to the linker. In another embodiment, more PAG groups 308 and fewer amino acids or fewer NTA molecules can be added to the linker, which creates a greater distance between attachment sites, thereby reducing the density of ligands that can bind to the linker. In one embodiment of the present disclosure, the density of linker attachment sites is adjustable.

[0266] Increasing the number of fixed ligands (e.g., proteins) bound to the linker increases the number of captured analyte molecules, which directly increases the SPR and LSPR signal intensities. However, one cannot simply increase the number of attached (e.g., -COOH that can be derived from NTA molecules) functional groups on the tunable linker and expect the analyte capture to increase linearly. The size and shape of the fixed ligand (e.g., protein) and analyte must also be considered. Considering the spatial limitations of the ligand and analyte, the linker-ligand can be adjusted to increase the analyte capture. In some embodiments where the ligand (e.g., protein) is larger, a higher density of attachment (e.g., -COOH that can be derived from NTA molecules) sites may spatially hinder the increase in the concentration of the fixed protein. Therefore, in some embodiments, the novel linker can be adjusted to increase the number of PAG units and reduce the number of amino acids or NTA sites 304. This embodiment will increase the length of the linker and reduce the density of attachment sites 304. In some embodiments, such as the present example, it is preferred to reduce the number of attachment sites (e.g., -COOH). In some embodiments, the -COOH site may be derived from one or more NTA molecules.

[0267] In other embodiments, when the ligand (e.g., protein) is not so large, a higher density of attachment sites may not have the above-mentioned spatial considerations, and it may actually be desirable to bind a higher concentration of the ligand (e.g., protein). Therefore, in some embodiments, the new linker can be adjusted to reduce the number of PAG units and increase the number of amino acid or NTA attachment sites 302. This embodiment will reduce the length of the spacer between the attachment sites, thereby increasing the density of attachment sites (e.g., -COOH) 302. In some embodiments, such as the present example, it is preferred to increase the number of attachment sites (e.g., -COOH). In some embodiments, the -COOH sites can be derived from one or more NTA molecules.

[0268] In some embodiments, the linker entity may be a branched PAG without the use of amino acids. A branched PAG may include branches that terminate with an attachment site for a ligand, such as a carboxylic acid site. In some embodiments, a branched PAG may include branches that terminate with an attachment site for a ligand, such as one or more NTA sites.

[0269] Examples of tunable linkers include, but are not limited to:

[0270] Cys X [—Gly Y —Asp A ] Z ;

[0271] Cys X [—Gly Y —GluA ] Z ;

[0272] Cys X [—Gly Y —Lys A ] Z ;

[0273] Cys X [—Gly Y —NTA A ] Z ;

[0274] Cys X [—PAG Y —Asp A ] Z ;

[0275] Cys X [—PAG Y —Glu A ] Z ;

[0276] Cys X [—PAG Y —Lys A ] Z ;

[0277] Cys X [—PAG Y —NTA A ] Z ;

[0278] Cys X [—NPC Y —Asp A ] Z ;

[0279] Cys X [—NPC Y —Glu A ] Z ;

[0280] Cys X [—NPC Y —Lys A ] Z ;

[0281] Cys X [—NPC Y —NTA A ] Z ;

[0282] Cys X [—(CH2)Y —Asp A ] Z ;

[0283] Cys X [—(CH2) Y —Glu A ] Z ;

[0284] Cys X [—(CH2) Y -List A ] Z ;

[0285] Cys X [—(CH2) Y —NTA A ] Z ;

[0286] With X [-Slide Y —Asp A ] Z ;

[0287] With X [-Slide Y —Glu A ] Z ;

[0288] With X [-Slide Y -List A ] Z ;

[0289] With X [-Slide Y —NTA A ] Z ;

[0290] With X [—PAG Y —Asp A ] Z ;

[0291] With X [—PAG Y —Glu A ] Z ;

[0292] With X [—PAG Y -List A ] Z ;

[0293] WithX [—PAG Y —NTA A ] Z ;

[0294] Of X [—NPC Y —Asp A ] Z ;

[0295] Of X [—NPC Y —Glu A ] Z ;

[0296] Of X [—NPC Y —Lys A ] Z ;

[0297] Of X [—NPC Y —NTA A ] Z ;

[0298] Of X [—(CH2) Y —Asp A ] Z ;

[0299] Of X [—(CH2) Y —Glu A ] Z ;

[0300] Of X [—(CH2) Y —Lys A ] Z ;

[0301] Of X [—(CH2) Y —NTA A ] Z ;

[0302] Yes X [—Gly Y —Asp A ] Z ;

[0303] Yes X [—Gly Y —Glu A ] Z ;

[0304] From the X [—Gly Y —Lys A ] Z ;

[0305] From the X [—Gly Y —NTA A ] Z ;

[0306] From the X [—PAG Y —Asp A ] Z ;

[0307] From the X [—PAG Y —Glu A ] Z ;

[0308] From the X [—PAG Y —Lys A ] Z ;

[0309] From the X [—PAG Y —NTA A ] Z ;

[0310] From the X [—NPC Y —Asp A ] Z ;

[0311] From the X [—NPC Y —Glu A ] Z ;

[0312] From the X [—NPC Y —Lys A ] Z ;

[0313] From the X [—NPC Y —NTA A ] Z ;

[0314] From the X [—(CH2) Y —Asp A ] Z ;

[0315] Yes X [—(CH2) Y —Glu A ] Z ;

[0316] Yes X [—(CH2) Y —Lys A ] Z ;

[0317] Yes X [—(CH2) Y —NTA A ] Z ;

[0318] SR X [—Gly Y —Asp A ] Z ;

[0319] SR X [—Gly Y —Glu A ] Z ;

[0320] SR X [—Gly Y —Lys A ] Z ;

[0321] SR X [—Gly Y —NTA A ] Z ;

[0322] SR X [—PAGE Y —Asp A ] Z ;

[0323] SR X [—PAGE Y —Glu A ] Z ;

[0324] SR X [—PAGE Y —Lys A ] Z ;

[0325] SR X [—PAGE Y —NTA A ] Z ;

[0326] SR X [—NPC Y —Asp A ] Z ;

[0327] SR X [—NPC Y —Glu A ] Z ;

[0328] SR X [—NPC Y —Lys A ] Z ;

[0329] SR X [—NPC Y —NTA A ] Z ;

[0330] SR X [—(CH2) Y —Asp A ] Z ;

[0331] SR X [—(CH2) Y —Glu A ] Z ;

[0332] SR X [—(CH2) Y —Lys A ] Z ;

[0333] SR X [—(CH2) Y —NTA A ] Z ;

[0334] NR X [—Gly Y —Asp A ] Z ;

[0335] NR X [—Gly Y —Glu A ] Z ;

[0336] NR X [—Gly Y —Lys A ]Z ;

[0337] NR X [—Gly Y —NTA A ] Z ;

[0338] NR X [—PAGE Y —Asp A ] Z ;

[0339] NR X [—PAGE Y —Glu A ] Z ;

[0340] NR X [—PAGE Y —Lys A ] Z ;

[0341] NR X [—PAGE Y —NTA A ] Z ;

[0342] NR X [—NPC Y —Asp A ] Z ;

[0343] NR X [—NPC Y —Glu A ] Z ;

[0344] NR X [—NPC Y —Lys A ] Z ;

[0345] NR X [—NPC Y —NTA A ] Z ;

[0346] NR X [—(CH2) Y —Asp A ] Z ;

[0347] NR X [—(CH2) Y —Glu A] Z ;

[0348] NR X [—(CH2) Y —Lys A ] Z ;

[0349] NR X [—(CH2) Y —NTA A ] Z ;

[0350] Cys X —Gly Y —Asp A ;

[0351] Cys X —Gly Y —Glu A ;

[0352] Cys X —Gly Y —Lys A ;

[0353] Cys X —Gly Y —NTA A ;

[0354] Cys X —PAG Y —Asp A ;

[0355] Cys X —PAG Y —Glu A ;

[0356] Cys X —PAG Y —Lys A ;

[0357] Cys X —PAG Y —NTA A ;

[0358] Cys X —NPC Y —Asp A ;

[0359] Cys X —NPC Y —Glu A ;

[0360] CysX —NPC Y -List A ;

[0361] Cys X —NPC Y —NTA A ;

[0362] Cys X —(CH2) Y —Asp A ;

[0363] Cys X —(CH2) Y —Glu A ;

[0364] Cys X —(CH2) Y -List A ;

[0365] Cys X —(CH2) Y —NTA A ;

[0366] With X -Slide Y —Asp A ;

[0367] With X -Slide Y —Glu A ;

[0368] With X -Slide Y -List A ;

[0369] With X -Slide Y —NTA A ;

[0370] With X —PAG Y —Asp A ;

[0371] With X —PAG Y —Glu A ;

[0372] With X —PAG Y -List A ;

[0373] Of X —PAG Y —NTA A ;

[0374] Of X —NPC Y —Asp A ;

[0375] Of X —NPC Y —Glu A ;

[0376] Of X —NPC Y —Lys A ;

[0377] Of X —NPC Y —NTA A ;

[0378] Of X —(CH2) Y —Asp A ;

[0379] Of X —(CH2) Y —Glu A ;

[0380] Of X —(CH2) Y —Lys A ;

[0381] Of X —(CH2) Y —NTA A ;

[0382] Yes X —Gly Y —Asp A ;

[0383] Yes X —Gly Y —Glu A ;

[0384] Yes X —Gly Y —Lys A ;

[0385] Yes X —Gly Y —NTA A ;

[0386] From the X —PAG Y —Asp A ;

[0387] From the X —PAG Y —Glu A ;

[0388] From the X —PAG Y —Lys A ;

[0389] From the X —PAG Y —NTA A ;

[0390] From the X —NPC Y —Asp A ;

[0391] From the X —NPC Y —Glu A ;

[0392] From the X —NPC Y —Lys A ;

[0393] From the X —NPC Y —NTA A ;

[0394] From the X —(CH2) Y —Asp A ;

[0395] From the X —(CH2) Y —Glu A ;

[0396] From the X —(CH2) Y —Lys A ;

[0397] From the X —(CH2) Y —NTA A ;

[0398] SR X —Gly Y —Asp A ;

[0399] SR X —Gly Y —Glu A ;

[0400] SR X —Gly Y —Lys A ;

[0401] SR X —Gly Y —NTA A ;

[0402] SR X —PAG Y —Asp A ;

[0403] SR X —PAG Y —Glu A ;

[0404] SR X —PAG Y —Lys A ;

[0405] SR X —PAG Y —NTA A ;

[0406] SR X —NPC Y —Asp A ;

[0407] SR X —NPC Y —Glu A ;

[0408] SR X —NPC Y —Lys A ;

[0409] SR X —NPC Y —NTA A ;

[0410] SR X —(CH2) Y —Asp A ;

[0411] SR X —(CH2) Y —Glu A ;

[0412] SR X —(CH2) Y —Lys A ;

[0413] SR X —(CH2) Y —NTA A ;

[0414] NR X —Gly Y —Asp A ;

[0415] NR X —Gly Y —Glu A ;

[0416] NR X —Gly Y —Lys A ;

[0417] NR X —Gly Y —NTA A ;

[0418] NR X —PAG Y —Asp A ;

[0419] NR X —PAG Y —Glu A ;

[0420] NR X —PAG Y —Lys A ;

[0421] NR X —PAG Y —NTA A ;

[0422] NR X —NPC Y —Asp A ;

[0423] NR X —NPC Y —Glu A ;

[0424] NR X —NPC Y —Lys A ;

[0425] NRX —NPC Y —NTA A ;

[0426] NR X —(CH2) Y —Asp A ;

[0427] NR X —(CH2) Y —Glu A ;

[0428] NR X —(CH2) Y —Lys A ;and

[0429] NR X —(CH2) Y —NTA A ;

[0430] wherein X ranges from 1 to 20, or from 2 to 8, or from 2 to 6, or from 2 to 4, and Y ranges from 0 to 50, or from 0 to 40, or from 0 to 30, or from 0 to 20, or from 0 to 10, or from 0 to 5; and A ranges from 1 to 50, or from 1 to 40, or from 1 to 30, or from 1 to 20, or from 1 to 10, or from 1 to 5; and Z may range from 1 to 10, or from 2 to 8, or from 2 to 6, or from 2 to 4.

[0431] Figure 4 An exemplary SPR or LSPR tunable linker molecule is illustrated, where the head group may be cysteine ​​(Cys), the spacer molecule may be, for example, PAG, and the attached amino acid may be glutamic acid or aspartic acid, and an example of an attachment site is a -COOH functional group. Figure 4 Description Cys X [—PAG Y —Asp A ] Z 402 and Cys X [—PAG Y —Glu A ] Z The example of 404, wherein X is 1, wherein the number of PAG units Y can vary as described above, and Z, the number of repeating -PAG-Glu and -PAG-Asp units is 4.

[0432] For the embodiments of the present disclosure, the following chemical formulas may also be applicable:

[0433] HG X —SG Y —AG A ;

[0434] wherein the arrangement of HG, SG and AG may be a linear or branched arrangement; and wherein there are an appropriate number of bonds between the chemical groups; wherein X represents the number of HG groups in a continuous arrangement or any other arrangement such as a branch in the head region of the linker; and wherein Y represents the number of spacer groups in a continuous arrangement or any other arrangement such as a branch in the body region of the linker; and wherein A represents the number of AG groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein X ranges from 1 to 20, or 2 to 8, or 2 to 6, or 2 to 4, and Y ranges from 0 to 50, or 0 to 40, or 0 to 30, or 0 to 20, or 0 to 10, or 0 to 5, and A may range from 1 to 10, or 1 to 8, or 1 to 6, or 1 to 4.

[0435] Formula I, Formula II, Formula III, and Formula IV (below) show additional exemplary linker structures.

[0436]

[0437]

[0438] These examples show further embodiments of the present disclosure, wherein the synthesized linker can further take into account not only the spatial requirements of the ligand, the density of the attachment sites, but also the adjustable hydrophobicity and hydrophilicity of the linker, spacer group, and attachment group. In these example structures, for example, cysteine ​​amino acids can provide a source of thiol functional groups for anchoring to a metal (e.g., gold) surface.

[0439] In some embodiments, the linker can be designed to have the following features, such as the following schematic, where HG is one or more head groups, LM is a lipophilic moiety, SG is a spacer group, and HM is a hydrophilic moiety:

[0440] HG X —LM L —SG Y —HM H ;

[0441] HG X —HM H —SG Y —LM L ;

[0442] HG X —SG Y —LM L —HM H ;

[0443] HG X —SGY —HM H —LM L ;

[0444] HG X —[LM L —SG Y —HM H ] Z ;

[0445] HG X —[LM L —SG Y ] Z —HM H ;and

[0446] HG X —LM L —[SG Y —HM H ] Z ;

[0447] wherein the arrangement of HG, LM, spacer groups and hydrophilic groups can be a linear or branched arrangement; and there are an appropriate number of bonds between the chemical groups; and wherein X represents the number of head 108 groups in a continuous arrangement or any other arrangement such as a branch in the head 108 region of the linker 120; and wherein L represents the number of lipophilic 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120; and wherein Y represents the number of spacer 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120; and wherein H represents the number of spacer 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120. and wherein Z represents the number of repeating groups within the brackets in a continuous arrangement or in any other arrangement such as a branched chain in the body 110 region of the linker 120; and wherein X ranges from 1 to 20, or 2 to 8, or 2 to 6, or 2 to 4; and L ranges from 0 to 25, or 1 to 22, or 1 to 20, or 1 to 15, or 1 to 10, or 1 to 5; and Y ranges from 0 to 50, or 0 to 40, or 0 to 30, or 0 to 20, or 0 to 10 or 1 to 5; and H ranges from 0 to 25, or 1 to 22, or 1 to 20, or 1 to 15, or 1 to 10, or 1 to 5; and Z can range from 1 to 10, or 2 to 8, or 2 to 6, or 2 to 4.

[0448] In some embodiments, the linker may include a hydrophobic (e.g., lipophilic) spacer group, such as an adjustable number of -(CH2)- groups. This arrangement can be represented by the following schematic diagram:

[0449] HGX —(CH2) L —AG A ;

[0450] HG X [—(CH2) L —AG A Z ;

[0451] HG X —(CH2) L —SG Y —AG A ;

[0452] HG X [—(CH2) L —SG Y —AG A Z ;

[0453] HG X —SG Y —(CH2) L —AG A ; and

[0454] HG X [—SG Y —(CH2) L —AG A Z ;

[0455] ​​​wherein the arrangement of HG, SG, CH2 groups and AG groups may be a linear or branched arrangement; and wherein there are an appropriate number of bonds between the chemical groups; and wherein X represents the number of head 108 groups in a continuous arrangement or any other arrangement such as a branch in the head 108 region of the linker 120; and wherein L represents the number of -(CH2)-spacer 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120; and wherein A represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120; and wherein Y represents the number of attachment groups 112 in a continuous arrangement or any other arrangement such as a branch in the body region 110 of the linker 120. and wherein Z represents the number of repeating groups within the brackets in a continuous arrangement or in any other arrangement such as a branched chain in the body 110 region of the linker 120; and wherein X ranges from 1 to 20, or 2 to 8, or 2 to 6, or 2 to 4, and L ranges from 0 to 25, or 1 to 22, or 1 to 20, or 1 to 15, or 1 to 10, or 1 to 5, and A ranges from 1 to 50, or 1 to 40, or 1 to 30, or 1 to 20, or 1 to 10, or 1 to 5, and Y ranges from 0 to 50, or 0 to 40, or 0 to 30, or 0 to 20, or 0 to 10, or 0 to 5; and Z can range from 1 to 10, or 2 to 8, or 2 to 6, or 2 to 4.

[0456] In some embodiments, the linker may include a hydrophobic (e.g., lipophilic) spacer group, such as an adjustable number of -(CH2)- groups. In some embodiments, the linker may include a hydrophilic (e.g., lipophobic) spacer group, such as an adjustable number of PAG groups. In some embodiments, the PAG may be PEG, POE, PPG, PBG, NPC, and combinations thereof (e.g., a linear or branched polymer comprising a combination of two or more different PAG subunits, such as two or more different PAG units selected from PEG, POE, PPG, PBG, and NPC subunits). In another embodiment, AG may be an adjustable number of NTA functional groups. This arrangement may be represented by the following schematic diagram:

[0457] HG X —(CH2) L —NTA A ;

[0458] HG X [—(CH2) L —NTA A ] Z ;

[0459] HG X —(CH2)L —PAG Y —NTA A ;

[0460] HG X [—(CH2) L —PAG Y —NTA A ] Z ;

[0461] HG X —PAG Y —(CH2) L —NTA A ;and

[0462] HG X [—PAG Y —(CH2) L —NTA A ] Z ;

[0463] wherein the arrangement of HG, PAG, CH2 groups and AG groups may be a linear or branched arrangement; and there are an appropriate number of bonds between the chemical groups; and wherein X represents the number of head 108 groups in a continuous arrangement or any other arrangement such as a branch in the head 108 region of the linker 120; and wherein L represents the number of -(CH2)-spacer 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120; and wherein Y represents the number of PAG spacer 110 groups in a continuous arrangement or any other arrangement such as a branch in the body 110 region of the linker 120; and wherein Z represents the number of repeating bracket groups in a continuous arrangement or any other arrangement such as a branched chain in the body 110 region of the linker 120; and wherein X ranges from 1 to 20, or 2 to 8, or 2 to 6, or 2 to 4, and L ranges from 0 to 25, or 1 to 22, or 1 to 20, or 1 to 15, or 1 to 10, or 1 to 5, and A ranges from 1 to 50, or 1 to 40, or 1 to 30, or 1 to 20, or 1 to 10, or 1 to 5, and Y ranges from 0 to 50, or 0 to 40, or 0 to 30, or 0 to 20, or 0 to 10, or 0 to 5; and Z can range from 1 to 10, or 2 to 8, or 2 to 6, or 2 to 4.

[0464] Examples

[0465] The following illustrative examples represent embodiments of the software applications, systems, and methods described herein and are not intended to be limiting in any way.

[0466] Example 1 - Synthesis of a monofunctional NTA linker without hydrophilic modification.

[0467] Provided herein is the synthesis of a monofunctional NTA linker having the structure of Formula I.

[0468]

[0469] The monofunctional NTA linker having the structure of Formula I can be synthesized in the laboratory using standard fmoc chemistry or commercially using an Applied Biosystems 433A peptide synthesizer. Unless otherwise specified, chemicals were purchased from Sigma-Aldrich (Millipore, St. Louis, MO, USA).

[0470] As shown in Scheme 1 (below), 300 mg of 2-Cl-trityl resin 1a was soaked in DCM for 30 minutes in a 10 mL solid phase peptide synthesis (SPPS) reactor. 2-Cl-trityl resin 1a was isolated by vacuum filtration and mixed with 3 mL of DMF containing 176 mg of Fmoc-Cys(Trt)-OH 1b and 210 μL of DIPEA in a peptide shaker (Kamush LP20PR). The mixture was shaken at room temperature (RT) for 60 minutes, and the resulting product 1c was isolated by vacuum filtration and washed three times with DMF and five times with DCM. To block the unreacted functional groups on the resin, 1c was shaken with a mixture of 5 mL of DCM / methanol / DIPEA (85:10:5) at room temperature for 60 minutes. Subsequently, 1c was isolated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. To remove the fmoc protecting group, 1c was mixed with 3 mL of 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM, and mixed with 509 mg of Fmoc-11-aminoundecanoic acid 1d, 558 mg of HATU, and 502 μL of DIPEA in 3 mL of DMF and shaken at room temperature for 150 minutes. The resulting product 1e was isolated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was tested for completion using the standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 1e is mixed with 3mL 20% piperidine in DMF, and exposure time (10 minutes for each exposure) is carried out in three steps. After deprotection, utilize DMF to wash resin three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times, and mix with 523mg fmoc-L-glutamic acid-OtBu 1f, 553mg HATU, and 502 μ L DIPEA in 3mL DMF, and shake at room temperature for 150 minutes. Separate the resulting product 1g by vacuum filtration, and utilize DMF to wash three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times. Use standard Kaiser test (ninhydrin test) to test the situation that reaction is completed. In order to remove the fmoc protecting group, resin is mixed with 3mL 20% piperidine in DMF, and exposure time (10 minutes for each exposure) is carried out in three steps.After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternating, and five times with DCM, and mixed with 522 mg IAA and 980 μL DIPEA in 2 mL DMF and shaken overnight at room temperature. The resulting product 1h was isolated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternating, and five times with DCM. The completion of the reaction was tested using the standard Kaiser test (ninhydrin test). 1h was mixed with a mixture of TFA / H2O / TIS (95:2.5:2.5) in a peptide shaker and shaken for 3 hours at room temperature. The resulting product 1i was precipitated in ether.

[0471] Scenario 1:

[0472]

[0473] Example 2 - Synthesis of a monofunctional NTA linker with a hydrophilic modification.

[0474] Provided herein is the synthesis of a monofunctional NTA linker having the structure of Formula II.

[0475]

[0476] The monofunctional NTA linker having the structure of Formula II can be synthesized in the laboratory using standard fmoc chemistry or commercially using an Applied Biosystems 433A peptide synthesizer. Unless otherwise specified, chemicals were purchased from Sigma-Aldrich (Millipore, St. Louis, MO, USA).

[0477] As shown in Scheme 2 (below), 300 mg of 2-Cl-trityl resin 2a was soaked in DCM for 30 min in a 10 mL solid phase peptide synthesis (SPPS) reactor. 2-Cl-trityl resin 2a was isolated by vacuum filtration and mixed with 176 mg of Fmoc-Cys(Trt)-OH 2b and 210 μL of DIPEA in 3 mL of DMF in a peptide shaker (Kamush LP20PR). The mixture was shaken at room temperature (RT) for 60 min, and the resulting product 2c was isolated by vacuum filtration and washed three times with DMF and five times with DCM. To block the unreacted functional groups on the resin, 2 was shaken with a mixture of 5 mL of DCM / methanol / DIPEA (85:10:5) at room temperature for 60 min. Subsequently, 2c was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. In order to remove the fmoc protecting group, 2c was mixed with 3mL 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM, and mixed with 509mg Fmoc-11-aminoundecanoic acid 2d, 558mg HATU, and 502 μL DIPEA in 3mL DMF, and vibrated at room temperature for 150 minutes. The resulting product 2e was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was completed using the standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 2e is mixed with 3mL 20% piperidines in DMF, and is exposed for 30 minutes in three steps (exposing for 10 minutes at a time). After the deprotection, DMF is utilized to wash the resin three times, DCM / methanol is utilized to alternately wash six times, and DCM is utilized to wash five times, and with 732mg fmoc-PEG 2f, 570mg HATU, and 502 μ L DIPEA in 3mL DMF, mix, and at room temperature vibrate for 150 minutes. The resulting product 2g is separated by vacuum filtration, and DMF is utilized to wash three times, DCM / methanol is utilized to alternately wash six times, and DCM is utilized to wash five times. The situation that the reaction is completed is tested using standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 2g is mixed with 3mL 20% piperidines in DMF, and is exposed for 30 minutes in three steps (exposing for 10 minutes at a time).After deprotection, utilize DMF to wash resin three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times, and mix with 523mg fmoc-L-glutamic acid-OtBu 2h, 553mg HATU, and 502 μ L DIPEA in 3mL DMF, and the mixture is vibrated at room temperature for 150 minutes. Separate the obtained product 2i by vacuum filtration, and utilize DMF to wash three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times. Use standard Kaiser test (ninhydrin test) to test the situation that reaction is completed. In order to remove fmoc protecting group, 2i is mixed with 3mL 20% piperidine in DMF, and the exposure time (10 minutes of each exposure) of 30 minutes is carried out in three steps. After deprotection, utilize DMF to wash resin three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times, and mix with 522mg IAA and 980 μ L DIPEA in 2mL DMF, and vibrate at room temperature overnight. The resulting product 2j was isolated by vacuum filtration and washed three times with DMF, six times with alternating DCM / methanol, and five times with DCM. The reaction was tested for completion using the standard Kaiser test (ninhydrin test). 2j was mixed with a mixture of TFA / H2O / TIS (95:2.5:2.5) in a peptide shaker and shaken at room temperature for 3 hours. The resulting product 2k was precipitated in ether.

[0478] Scenario 2:

[0479]

[0480] Example 3 - Synthesis of a bifunctional NTA linker without hydrophilic modification.

[0481] Provided herein is the synthesis of a bifunctional NTA linker having the structure of Formula III.

[0482]

[0483] The bifunctional NTA linker having the structure of Formula III can be synthesized in the laboratory using standard fmoc chemistry or commercially using an Applied Biosystems 433A peptide synthesizer. Unless otherwise specified, chemicals were purchased from Sigma-Aldrich (Millipore, St. Louis, MO, USA).

[0484] As shown in Scheme 3 (below), 300 mg of 2-Cl-trityl resin 3a was soaked in DCM for 30 min in a 10 mL solid phase peptide synthesis (SPPS) reactor. 2-Cl-trityl resin 3a was isolated by vacuum filtration and mixed with 176 mg of Fmoc-Cys(Trt)-OH 3b and 210 μL DIPEA in 3 mL DMF in a peptide shaker (Kamush LP20PR). The mixture was shaken at room temperature (RT) for 60 min, and the resulting product 3c was isolated by vacuum filtration and washed three times with DMF and five times with DCM. To block the unreacted functional groups on the resin, 3c was shaken with a mixture of 5 mL DCM / methanol / DIPEA (85:10:5) at room temperature for 60 min. Subsequently, 3c was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. In order to remove the fmoc protecting group, 3c was mixed with 3mL 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM, and mixed with 509mgFmoc-11-aminoundecanoic acid 3d, 558mg HATU, and 502μL DIPEA in 3mL DMF, and vibrated at room temperature for 150 minutes. The resulting product 3e was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was completed using the standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 3e is mixed with 3mL 20% piperidines in DMF, and exposure time (10 minutes for each exposure) is carried out in three steps. After deprotection, DMF is utilized to wash the resin three times, DCM / methanol is utilized to alternately wash six times, and DCM is utilized to wash five times, and with 887mg fmoc-Lys (fmoc) -OH 3f, 570mg HATU, and 502 μ L DIPEA are mixed in 3mL DMF, and at room temperature vibrate 150 minutes. The resulting product 3g is separated by vacuum filtration, and DMF is utilized to wash three times, DCM / methanol is utilized to alternately wash six times, and DCM is utilized to wash five times. The situation that standard Kaiser test (ninhydrin test) test reaction is completed is used. In order to remove the fmoc protecting group, 3g is mixed with 3mL 20% piperidines in DMF, and exposure time (10 minutes for each exposure) is carried out in three steps.After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM, and mixed with 1,046 mg fmoc-L-glutamic acid-OtBu 3h, 1,106 mg HATU, and 1,004 μL DIPEA in 3 mL DMF, and the mixture was shaken at room temperature for 150 minutes. The resulting product 3i was isolated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was tested for completion using the standard Kaiser test (ninhydrin test). To remove the fmoc protecting group, 3i was mixed with 3 mL 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After each exposure, the resin was isolated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. After deprotection, the resin was mixed with 1,044 mg IAA and 1,960 μL DIPEA in 3 mL DMF and shaken overnight at room temperature. The resulting product 3j was isolated by vacuum filtration and washed three times with DMF, six times with alternating DCM / methanol, and five times with DCM. The completion of the reaction was tested using the standard Kaiser test (ninhydrin test). 3j was mixed with a mixture of TFA / H2O / TIS (95:2.5:2.5) in a peptide shaker and shaken for 3 hours at room temperature. The resulting product 3k was precipitated in diethyl ether.

[0485] Solution 3:

[0486]

[0487] Option 3 (continued):

[0488]

[0489] Example 4 - Synthesis of a bifunctional NTA linker with hydrophilic modification.

[0490] Provided herein is the synthesis of a bifunctional NTA linker having the structure of Formula IV.

[0491]

[0492] The bifunctional NTA linker having the structure of Formula IV can be synthesized in the laboratory using standard fmoc chemistry or commercially using an Applied Biosystems 433A peptide synthesizer. Unless otherwise stated, chemicals were purchased from Sigma-Aldrich (Millipore, St. Louis, MO, USA).

[0493] As shown in Scheme 4 (below), 300 mg of 2-Cl-trityl resin 4a was soaked in DCM for 30 min in a 10 mL solid phase peptide synthesis (SPPS) reactor. 2-Cl-trityl resin 4a was isolated by vacuum filtration and mixed with 176 mg of Fmoc-Cys(Trt)-OH 4b and 210 μL DIPEA in 3 mL DMF in a peptide shaker (Kamush LP20PR). The mixture was shaken at room temperature (RT) for 60 min, and the resulting product 4c was isolated by vacuum filtration and washed three times with methanol and five times with DCM. To block the unreacted functional groups on the resin, 4c was shaken with a mixture of 5 mL DCM / methanol / DIPEA (85:10:5) at room temperature for 60 min. Subsequently, 4c was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. To remove the fmoc protecting group, 4c was mixed with 3mL 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM, and mixed with 509mg Fmoc-11-aminoundecanoic acid 4d, 558mg HATU, and 502μL DIPEA in 3mL DMF, and vibrated at room temperature for 150 minutes. The resulting product 4e was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was completed using the standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 4e is mixed with 3mL20% piperidines in DMF, and exposure time (10 minutes for each exposure) is carried out in three steps for 30 minutes. After deprotection, resin is put back in peptide oscillator, and mixed with 887mg Fmoc-D-Lys(ivDde)-OH 4f, 570mg HATU, and 502 μ L DIPEA in 3mL DMF, and at room temperature vibrates for 150 minutes. The resulting product 4g is separated by vacuum filtration, and DMF is washed three times, DCM / methanol is alternately washed six times, and DCM is washed five times. The reaction is completed using standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 4g is mixed with 3mL20% piperidines in DMF, and exposure time (10 minutes for each washing) is carried out in three steps for 30 minutes.After deprotection, utilize DMF to wash resin three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times, and mix with 732mgfmoc-PEG 4h, 570mg HATU, and 502 μ L DIPEA in 3mL DMF, and the mixture is shaken at room temperature 150 minutes. Separate the obtained product 4i by vacuum filtration, and utilize DMF to wash three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times. Use standard Kaiser test (ninhydrin test) to test the situation that reaction is completed. In order to remove fmoc and iv.Dde protecting groups, 4i is mixed with 5mL2% hydrazine in DMF, and exposure time (3 minutes for each exposure) is carried out in three steps for 9 minutes. After each exposure, separate resin by vacuum filtration, and utilize DMF to wash three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times. After deprotection, the resin was mixed with 1,046 mg fmoc-L-glutamic acid-OtBu 4j, 1,106 mg HATU, and 1,004 μL DIPEA in 3 mL DMF and shaken for 150 minutes at room temperature. The resulting product 4k was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was completed using the standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 4k was mixed with 3 mL 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After deprotection, the resin was washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM, and mixed with 1,044 mg IAA and 1,960 μL DIPEA in 3 mL DMF, and shaken overnight at room temperature. The resulting product 41 was isolated by vacuum filtration and washed three times with DMF, six times with alternating DCM / methanol, and five times with DCM. The reaction was tested for completion using the standard Kaiser test (ninhydrin test). 41 was mixed with a mixture of TFA / H2O / TIS (95:2.5:2.5) in a peptide shaker and shaken at room temperature for 3 hours. The resulting product 4m was precipitated in ether.

[0494] Solution 4:

[0495]

[0496] Option 4 (continued):

[0497]

[0498] Example 5 - Coating of sensor surfaces using NTA linkers.

[0499] NTA linkers were synthesized as described in Examples 1-4 (above) and further disposed on a metal (eg, gold) surface to generate a sensor for an analyte bound in a sample.

[0500] Glass chip sensors:

[0501] Dissolve a thiol-terminated NTA linker (e.g., Formula I, Formula II, Formula III, or Formula IV above) in DI H2O at a concentration of 1 mM. Clean the bare gold OpenSPR using 40 W oxygen plasma. TM Sensor chip was incubated for 30 seconds and placed in a petri dish. 100 μL of NTA solution was pipetted onto the surface of each sensor. 1 to 2 mL of DI H2O was added to the petri dish to prevent drying during incubation. The petri dish lid was placed and sealed with plastic wrap and incubated overnight. The next day, the sensor was washed with DI H2O, dried with a stream of nitrogen gas, and stored dry.

[0502] Fiber Optic Sensors:

[0503] A thiol-terminated NTA linker (e.g., Formula I, Formula II, Formula III, or Formula IV described above) was dissolved in DI H2O at a concentration of 1 mM and transferred to a 128-well plate. TM Bare gold fiber (128Alto TM A bare gold fiber was placed in a 128 fiber rack and cleaned by immersing it in DI H2O and then performing three 5-minute cycles in an ultrasonic generator. The fiber was transferred to a drying chamber and dried at room temperature for 5 minutes. The dried fiber was cleaned for 30 seconds using 40 watts of oxygen plasma, immediately immersed in an NTA aqueous solution, and incubated overnight. The next day, the sensor was washed by immersing the fiber in a 128-well plate containing DIH2O three times and dried in a drying chamber for 5 minutes. The NTA sensor made was dried and stored.

[0504] Example 6 - Fabrication of sensors with CMD-NTA linkers.

[0505] Provided herein is the preparation (ie, synthesis) of a sensor modified with a CMD-NTA linker having the structure shown below.

[0506]

[0507] The CMD-NTA modified sensor having the structure of Formula V can be synthesized in the laboratory using standard fmoc chemistry or commercially using an Applied Biosystems 433A peptide synthesizer. Unless otherwise stated, chemicals were purchased from Sigma-Aldrich (Millipore, St. Louis, MO, USA).

[0508] As shown in Scheme 5 (below), 300 mg of Rink amide resin 5a was soaked in DCM for 30 minutes in a 10 mL solid phase peptide synthesis (SPPS) reactor. Rink amide resin 5a was separated by vacuum filtration. Rink amide resin 5a was mixed with 3 mL of 20% piperidine in DMF and exposed for 30 minutes in three steps (10 minutes each exposure). After each exposure, the resin was separated by vacuum filtration and washed three times with methanol and five times with DCM. After deprotection, the resin was mixed with 863 mg of Fmoc-Lys(ivDde)-OH 5b, 570 mg of HATU, and 502 μL of DIPEA in 3 mL of DMF and shaken at room temperature for 150 minutes. The resulting product 5c was separated by vacuum filtration and washed three times with DMF, six times with DCM / methanol alternately, and five times with DCM. The reaction was tested for completion using the standard Kaiser test (ninhydrin test). In order to remove the fmoc protecting group, 5c is mixed with 3mL 20% piperidines in DMF, and the exposure time of 30 minutes (10 minutes for each exposure) is carried out in three steps. After deprotection, utilize DMF to wash resin three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to be combined in 523mg fmoc-L-glutamic acid, α-tert-butyl ester 5d, 553mg HATU in 3mL DMF, and 502 μ L DIPEA to wash five times, and at room temperature vibrate 150 minutes. Separate the resulting product 5e by vacuum filtration, utilize DMF to wash three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times. Use standard Kaiser test (ninhydrin test) to test the situation that reaction is completed. In order to remove the fmoc protecting group, 5e is mixed with 3mL 20% piperidines in DMF, and the exposure time of 30 minutes (10 minutes for each exposure) is carried out in three steps. After deprotection, utilize DMF to wash resin three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times, and mix with 522mg IAA and 980 μ L DIPEA in 2mL DMF, and the mixture is shaken at room temperature overnight. The resulting product 5f is separated by vacuum filtration, and utilizes DMF to wash three times, utilizes DCM / methanol to alternately wash six times, and utilizes DCM to wash five times. The situation that standard Kaiser test (ninhydrin test) is used to test the reaction completion. In order to remove fmoc and iv.Dde protecting groups, 4i is mixed with 5mL 2% hydrazine in DMF, and exposure time (3 minutes for each exposure) is carried out in three steps for 9 minutes. After each exposure, separate resin by vacuum filtration, and utilize DMF to wash three times, utilize DCM / methanol to alternately wash six times, and utilize DCM to wash five times.The resin was mixed with a mixture of TFA / H2O / TIS (95:2.5:2.5) in a peptide shaker and shaken at room temperature for 3 hours. 5 g of the obtained product was precipitated in diethyl ether.

[0509] Subsequently, 203.6mg CMD5 5h, 23.8mg EDC, and 13.8mg NHS were dissolved in 10mL deionized water (DIH2O) and the resulting solution was added to a solution containing 42.6mg TTEA 5i dissolved in 10mL DMF. The resulting mixture was stirred at room temperature overnight using a magnetic stirrer. The product was then precipitated in 80mL acetone and separated using a centrifuge (2500rpm, 10 minutes), washed with 20mL acetone, and dried under vacuum for 3 hours to obtain a white powder. The white powder was dissolved in 5 to 10mL of TFA / H2O / TIS (95:2.5:2.5) mixture for 2 hours. Afterwards, 5j was precipitated in ether, vacuum dried for 3 hours, and stored in a -20 refrigerator under a nitrogen atmosphere.

[0510] In the next step, 5j was dissolved in DI H2O at a concentration of 1 mM and coated on the gold surface of the SPR sensor and incubated overnight at room temperature. The next day, the sensor was washed thoroughly with DI H2O to remove any unbound 5j and dried using a nitrogen stream. The surface was then activated by incubating in EDC / NHS 0.25M:0.1M solution for 1 hour and washed with DI water. The sensor was reacted with a 100 mM solution of Nα,Nα-bis(carboxymethyl)-L-lysine hydrate 5l at room temperature overnight, the solution consisting of IPA:MQ:Et3N in a ratio of 63:32:5. The CMD-NTA-modified sensor 5m was washed with IPA / DI water, dried using a nitrogen stream, and stored under dry conditions.

[0511] Solution 5:

[0512]

[0513] Option 5 (continued):

[0514]

[0515] Option 5 (continued):

[0516]

[0517] Example 7 - Detection of IL-6 / IL-6R using CMD-NTA.

[0518] Au NPs coated with CMD-NTA were prepared as described in Example 6 (above). Au NPs were deposited on a sensor chip and integrated into a LSPR system in one reference channel (8 channels) and one sample channel (8 channels).

[0519] The sensor was exposed to a series of solutions within the microfluidic cartridge system. The volume of solution for each exposure was approximately 2 droplet units ("du") in the microfluidic system, equivalent to approximately 1.4 μL, and was dispensed from a solution reservoir within the cartridge.

[0520] As a washing step, the sensor tip was exposed to PBS buffer at pH 7.4 containing 0.1% T20 surfactant, which was Figure 5 A small peak at about 500 seconds was observed.

[0521] The system was calibrated by introducing 4% and 32% glycerol solutions, which were Figure 5 The first and second peaks were observed at around 2000 seconds, respectively.

[0522] The sensor was then exposed to 10 mM HCl solution for cleaning, which can be Figure 5 A peak was observed at around 3000 seconds.

[0523] The sensors were then exposed to a solution of 0.35 M EDTA (pH 8) containing 0.1% T20 to remove any possible transition metals from the surface, which could be Figure 5 A peak was observed at around 4000 seconds.

[0524] Inject 40 mM NiCl2 aqueous solution to form a chelate with NTA functional groups, which can be Figure 5 A peak was observed at around 5000 seconds.

[0525] Next, a solution of anti-IL-6 ligand (IL-6R protein human recombinant (His-Tag) 40 kDA, PBS pH 7.4) was introduced into the response channel (grey trace) and the reference channel (black trace) with his-strep protein (0.5 mg / ml), which can be Figure 5 A peak at about 6000 seconds was observed.

[0526] IL-6 analyte was then introduced into the reference and response channels, resulting in a peak signal in the response channel (at Figure 5 This region of the sensorgram is flat in the reference channel, confirming a positive response to IL-6 in this sensor configuration (gray trace at about 8500 seconds). Figure 5 (black trace at about 8500 s).

[0527] To show the reversibility of sensor immobilization and reusability, the sensor was exposed to 10 mM HCl solution (which can be Figure 5 A valley around 9000 s was observed in the experiment), and then exposed to a 0.5 M imidazole solution in DI H2O (which can be Figure 5 The light signal shifted back to the baseline, indicating that IL-6 was not present on the linker surface.

[0528] Ligand exposure and regeneration were repeated five times. Figure 6 is a graph showing the IL-6 ligand immobilization response of four independent channels. Figure 7 is a graph showing the IL-6 analyte immobilization response for four independent channels.

[0529] Although preferred embodiments of the present disclosure have been shown and described herein, it will be understood by those skilled in the art that such embodiments are provided by way of example only. The present disclosure is not intended to be limited by the specific examples provided in the specification. Although the present disclosure has been described with reference to the above description, however, the description and illustration of the embodiments herein are not intended to be interpreted in a limiting sense. Those skilled in the art will now think of many variations, changes and substitutions without departing from the present disclosure. In addition, it should be understood that all aspects of the present disclosure are not limited to the specific descriptions, configurations or relative proportions described herein, which depend on various conditions and variables. It should be understood that various alternatives to the disclosed embodiments described herein may be adopted when implementing the present disclosure. Therefore, it is expected that the present invention should also cover any such alternatives, modifications, variations or equivalents. It is expected that the following claims define the scope of the present disclosure, and methods and structures within the scope of such claims and their equivalents should be covered thereby.

Claims

1. A nitrilotriacetic acid linker, Features: The nitrilotriacetic acid linker has the following chemical formula: wherein the AA group comprises a linear or branched natural or synthetic amino acid group, and the amino acid group comprises one or more amino acids; The optional spacer comprises a linear or branched carbon chain comprising one or more amino acids, a polymer moiety, or any combination thereof, wherein in the absence of the spacer, the AA group is coupled to the one or more nitrilotriacetic acid groups NTA; The nitrilotriacetic acid group NTA includes one or more nitrilotriacetic acid functional groups; Wherein R is H, a short-chain alkyl group, or a primary aminotriacetic acid group; Wherein n is the number of spacers in the linker; wherein o is the number of nitrilotriacetic acid groups in the linker; and where p is The number of parts.

2. The nitrilotriacetic acid linker according to claim 1, Features: The AA group includes 1 to 10 amino acids.

3. The nitrilotriacetic acid linker according to claim 1, Features: The AA group includes a cysteine ​​or a methionine amino acid.

4. The nitrilotriacetic acid linker according to the preceding claims, Features: The spacer includes a carbon chain.

5. The nitrilotriacetic acid linker according to any one of claims 1 to 3, Features: The spacer includes a PAG group having one or more PAG units.

6. The nitrilotriacetic acid linker according to any one of claims 1 to 3, Features: The spacer includes a PEG group having one or more PEG units.

7. The nitrilotriacetic acid linker according to any one of the preceding claims, Features: n comprises 0 to 50 spacers.

8. The nitrilotriacetic acid linker according to any one of the preceding claims, Features: The number of n is 1 to 10 nitrilotriacetic acid groups.

9. The nitrilotriacetic acid linker according to any one of the preceding claims, Features: p includes 1 to 10 parts.

10. The nitrilotriacetic acid linker according to any one of the preceding claims, Features: The one or more nitrilotriacetic acid groups are configured to couple to a ligand and / or an analyte.

11. A surface plasmon resonance or localized surface plasmon resonance sensor, Features: The sensor comprises: (a) a substrate, wherein the substrate comprises a solid support coated with a metal layer; and (b) a nitrilotriacetic acid linker as claimed in any one of the preceding claims; (c) wherein the AA group of the nitrilotriacetic acid linker is coupled to the metal layer; and (d) wherein one or more nitrilotriacetic acid functional groups of the linker are capable of binding to one or more ligands and / or analytes.

12. The sensor according to claim 11, Features: The sensor includes a substrate and a coating, and the AA groups are covalently coupled to the coating.

13. The sensor according to claim 12, Features: The substrate is selected from the group consisting of a silicon substrate, a glass substrate, a polystyrene substrate, and an agarose substrate.

14. The sensor according to any one of claims 12 to 13, Features: The coating includes a first inner coating and a second outer coating.

15. The sensor according to claim 14, Features: The first inner coating layer includes a polyelectrolyte or a poly(allylamine hydrochloride).

16. The sensor according to claim 14, Features: The second outer coating layer includes a metal coating layer, a gold film, a metal nanoparticle coating layer, or a gold nanoparticle coating layer.

17. A method of detecting an analyte in a fluid using a surface plasmon resonance (SPR or LSPR) sensor, Features: The method comprises: A surface plasmon resonance or localized surface plasmon resonance sensor comprising a surface, the surface comprising a solid support, the solid support coated with a metal layer and having a nitrilotriacetic acid linker attached to the metal layer, wherein the nitrilotriacetic acid linker comprises the nitrilotriacetic acid linker of any one of claims 1 to 10; and Optionally, one or more ligands, said one or more ligands being coupled to said nitrilotriacetic acid linker; contacting a fluid containing an analyte with a surface plasmon resonance or localized surface plasmon resonance sensor; and An optical signal is measured to detect a change in the optical signal in response to the contacting to thereby measure an analyte in the fluid.

18. A method for preparing a sensor coupled to a nitrilotriacetic acid linker as claimed in any one of claims 1 to 10, Features: The method comprises: providing a substrate; coupling a first AA group to the substrate to produce substrate-AA; Optionally, coupling a spacer to the first AA group to generate a substrate-AA-spacer, wherein the spacer comprises an amino acid at a first end of the spacer; and The terminal amino acid is reacted with a first reagent to generate a primary aminotriacetic acid linker.

19. The method of claim 18, Features: The substrate is selected from the group consisting of a silicon substrate, a glass substrate, a polystyrene substrate, and an agarose substrate.

20. The method according to any one of claims 18 to 19, Features: The AA group includes a substrate coupling group and an α-amino group.

21. The method according to any one of claims 18 to 20, Features: The spacer includes a first coupling group at a first site, a second coupling group at a second site, and optionally a third coupling group at a third site, wherein the first coupling group, the second coupling group and the optional third coupling group may be the same or different chemical functional groups.

22. The method according to any one of claims 19 to 21, Features: The first AA group further comprises one or more protecting groups.

23. The method of claim 22, Features: The one or more protecting groups on the first AA group include one or more trityl functional groups and / or one or more fmoc functional groups.

24. The method of claim 23, Features: The AA group includes an fmoc-protected α-amino group, a trityl-protected thiol functional group and a carboxyl group, and the carboxyl group reacts with a substituent on the substrate to be covalently bonded to the substrate.

25. The method of claim 23, Features: A second reagent is used to remove the fmoc-protected α-amino group of the AA group to obtain a deprotected α-amino group.

26. The method according to any one of claims 18 to 25, Features: The spacer further comprises one or more protecting groups.

27. The method of claim 26, Features: The one or more protecting groups on the spacer include one or more fmoc functional groups and one or more tert-butyl functional groups.

28. The method of claim 26, Features: The spacer includes an fmoc-protected amino group and a carboxyl group, and the carboxyl group reacts with the deprotected α-amino group on the AA group to be covalently bonded to the AA group.

29. The method according to any one of claims 24 to 28, Features: A second reagent is used to remove the fmoc-protected amino group of the spacer to obtain a functional group, and wherein the functional group is reacted with a second AA to obtain a deprotected amino group.

30. The method of claim 29, Features: The second AA includes one or more protecting groups.

31. The method of claim 30, Features: The one or more protecting groups on the second AA include one or more fmoc functional groups and / or one or more tert-butyl functional groups.

32. The method of any one of claims 30 to 31, Features: The second AA includes an fmoc-protected α-amino group, the tert-butyl functional group and a carboxyl group, and the carboxyl group reacts with the deprotected amino group on the spacer to be covalently bonded to the spacer.

33. The method of claim 32, Features: The fmoc-protected α-amino group on the second AA is removed to produce a deprotected α-amino group.

34. The method of claim 33, Features: The deprotected α-amino group is reacted with a second reagent to generate an NTA-tBu functional group.

35. The method of any one of claims 33 to 34, Features: The first reagent is used to remove the tert-butyl protecting group on the second AA to generate the nitrilotriacetic acid linker.

36. The method of any one of claims 18 to 35, Features: The spacer includes a hydrophilic modification.

37. The method of claim 36, Features: The hydrophilic modification includes a PAG group having one or more PAG units.

38. The method of claim 36, Features: The hydrophilic modification includes a PEG group having one or more PEG units.

39. The method of any one of claims 18 to 38, Features: The nitrilotriacetic acid linker is separated from the substrate.

40. The method of any one of claims 18 to 39, Features: The first AA group includes fmoc-D-Cys(Trt)-OH or Fmoc-D-Met-OH.

41. The method of any one of claims 18 to 39, Features: The first AA group includes a series of amino acids, wherein one amino acid includes a moiety for attachment to the substrate and another amino acid includes a moiety having an alpha amino group adjacent to a carboxyl group.

42. The method of any one of claims 18 to 41, Features: The spacer includes fmoc-11-aminoundecanoic acid.

43. The method of any one of claims 22 to 42, Features: The second AA includes Fmoc-Glu-OtBu.

44. The method of any one of claims 18 to 43, Features: The first reagent includes iodoacetic acid and diisopropylethylamine.

45. The method of any one of claims 18 to 43, Features: The second reagent includes 20% piperidine in a solution of dimethylformamide, trifluoroacetic acid and triisopropylsilane or trifluoroacetic acid, dimethyl sulfoxide and anisole.

46. ​​A sensor for reversibly capturing a plurality of analytes in a sample, Features: The sensor comprises: a metal nanoparticle configured to generate an optical signal; a substrate disposed on a portion of the surface of the metal nanoparticles; and A plurality of multidentate groups are bound to the substrate, wherein each multidentate group of the plurality of multidentate groups chelates a metal ion.

47. The sensor of claim 46, Features: The matrix includes a polysaccharide, a polysaccharide derivative, a polymer, a functionalized polymer, a protein, or a combination thereof.

48. The sensor of claim 47, Features: The matrix includes dextran or carboxymethylated dextran.

49. A sensor as claimed in any one of claims 46 to 48, Features: The metal ion includes a transition metal ion.

50. The sensor of claim 49, Features: The transition metal ion is selected from the group consisting of nickel, iron, cobalt, copper, zinc, or a combination thereof.

51. A sensor as claimed in any one of claims 46 to 50, Features: The plurality of polydentate groups include nitrilotriacetic acid, tris-(2-aminoethyl)amine, or a combination thereof.

52. A sensor as claimed in any one of claims 46 to 51, Features: The matrix includes dextran, and the plurality of tridentate groups are nitrilotriacetic acid.

53. A sensor as claimed in any one of claims 46 to 52, Features: The matrix includes a matrix thickness of about 1 nm to about 100 nm.

54. A sensor as claimed in any one of claims 46 to 53, Features: The sensor includes a density of multidentate groups ranging from about 1% to about 100%.

55. A sensor as claimed in any one of claims 46 to 53, Features: The sensor includes a density of multidentate groups ranging from about 25% to about 75%.

56. A sensor as claimed in any one of claims 46 to 54, Features: The matrix is ​​covalently bonded to the metal nanoparticles.

57. A method of forming a sensor medium, Features: The method comprises: thiolation of a matrix material to provide a thiolated matrix material; adding at least one multidentate group to the thiolated matrix material to provide a modified matrix material; and The modified matrix material is disposed on a portion of a surface of a metal substrate.

58. The method of claim 57, Features: A substrate material is thiolated to provide a thiolated substrate material, and then at least one multidentate group is added to the thiolated substrate material to provide a modified substrate material.

59. The method of claim 57 or 58, Features: Thiolating a host material includes combining the host material with an amine or a derivative thereof.

60. The method of claim 59, Features: The amine includes monomercaptoalkylamine.

61. The method of claim 57, Features: Each of the at least one multidentate group comprises -SR, -OR, -NR 2 , -COOR, -CO, heterocycloalkyl, or a combination thereof, wherein R is independently H, a substituted or unsubstituted C 1 -C 4 alkyl, or a combination thereof.

62. The method of claim 61, Features: The at least one multidentate group is nitrilotriacetic acid, tris-(2-aminoethyl)amine, tris(hydroxymethyl)aminomethane, or a combination thereof.

63. The method of claim 57, Features: The metal substrate includes metal nanoparticles.

64. The method of any one of claims 57 to 63, Features: The method further comprises chelating at least one polydentate group with a metal ion.

65. The method of claim 64, Features: The metal ion comprises a transition metal ion selected from nickel, iron, cobalt, copper, calcium, zinc, or a combination thereof.

66. A method of determining the presence of an analyte in a sample, Features: The method comprises: Providing a sensor according to any one of claims 46 to 56; contacting the sensor with the sample, the sample comprising the analyte; The analyte binds to the sensor to generate a signal corresponding to the analyte.